Search this site

Nelson Advisors referenced in DC Advisory's 'European Healthcare M&A finds its pulse' report Nelson Advisors Thought Leadership article 'Corporate Divestitures in European Healthcare Technology: Trends in 2025' has been referenced in DC Advisory's 'European Healthcare M&A finds its pulse' report dated October 14, 2025. Source: https://www.dcadvisory.com/news-deals-insights/insights/dc-discusses-european-healthcare-ma-finds-its-pulse/ After two challenging years, the European Healthcare M&A market is showing renewed momentum. Globally, activity remains around 40% below peak levels, but sentiment is improving, pipelines are rebuilding, and investor appetite is returning.1 While deal volume remains subdued, a significant spike in deal value confirms that large, high-conviction transactions are returning.2 Nevertheless, higher interest rates, financing costs, and regulatory uncertainty have weighed on activity.3 DC Advisory’s European Healthcare team analyses the trends shaping the market and what they signal for the future, including Asian and US investors are increasingly targeting Europe, with cross-border activity rising Return of the relationship-driven advisory model The growth engines of European Healthcare M&A In the latest DC Discusses article, our Healthcare team discusses M&A trends, investor appetite, and the outlook for the sector. Nelson Advisors referenced in DC Advisory's 'European Healthcare M&A finds its pulse' report Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

European MedTech and HealthTech valuation landscape in October 2025 The European MedTech and HealthTech valuation landscape in October 2025 exhibits significant divergence by sub-sector, with a clear premium placed on innovative, high-growth and recurring revenue business models, especially those powered by AI. Here is a breakdown of the valuation trends and multiples by sub-sector: I. MedTech / Digital Health Valuation Multiples by Sub-Sector (Q4 2025) Valuation multiples for traditional MedTech and the innovative HealthTech segments differ based on growth profile, asset-light nature, and intellectual property. Sub-Sector / Business Model Key Multiples (EV/Revenue) Key Multiples (EV/EBITDA) Valuation Drivers / Context AI-Driven Diagnostics & Solutions 6.0x – 8.0x+ (Premium) 14.0x+ Highest Premiums. Driven by proprietary algorithms, proven clinical validation, scalability, and deep integration into clinical workflows (EHRs/imaging). AI is the single biggest valuation catalyst. Traditional Medical Devices(Profitable) 4.0x – 6.0x.(Average) 10.0x – 14.0x Includes established surgical, orthopaedic, and non-digital medical device companies. Multiples are stable but lower than high-tech segments, driven by market share, manufacturing scale, and product longevity. Value-Based Care Solutions 5.5x – 7.0x 12.0x – 15.0x Includes remote patient monitoring, population health, and chronic disease management platforms. Premium reflects proven cost savings, improved outcomes, and alignment with government/payer priorities. Telehealth & Advanced Analytics 6.0x – 8.0x+ 14.0x+ (High Growth) Premium driven by scalable software platforms, recurring subscription revenue (SaaS model), high gross margins, and large addressable markets. Digital Health / HealthTech (General) 4.0x – 6.0x.(Average) 10.0x – 14.0x The general benchmark for HealthTech companies. Multiples have moderated from their 2021/2022 peaks but remain robust for quality assets. Smaller / Unprofitable Startups 3.0x – 4.0x. (Compression) N/A (Negative EBITDA) Valuations are compressed unless the company possesses highly differentiated, "must-have" technology with a clear strategic fit for a larger acquirer. Comparative EBITDA Multiples for Private Healthcare Segments While general MedTech EBITDA multiples are highly specific to the company's size and profitability, comparative data from early 2025 shows a sector hierarchy: Private Healthcare Sub-Sector (US/Europe) Median EV/EBITDA Multiples ($5M-$10M EBITDA) Medical Device 10.4x Plastic Surgery (High-growth, non-essential) 11.3x Hospitals / Facilities 9.7x Medical Practices 8.8x MedTech (General) 8.4x II. Sub-Sector Specific Trends Driving Premiums 1. Robotics and Minimally Invasive Surgery (MIS) Trend: The surgical robotics market is experiencing high growth (CAGR of ∼17% globally projected through 2035). Valuation Impact: Companies in this space, especially those with unique or next-generation platforms, continue to be a primary target for large strategic M&A, sustaining high revenue multiples. Acquisitions focus on expanding into new specialties (beyond urology/gynecology) such as neurosurgery and orthopedic joint replacement. 2. Medical Diagnostics (Including IVD) Trend: The second-highest funded digital health cluster in H1 2025. Investment is strongly focused on AI-powered diagnosis tools, medical imaging analysis, and omics related diagnostics. Valuation Impact: Diagnostic firms that integrate AI to improve accuracy and efficiency—especially those with a clear path to regulatory approval and reimbursement—are seeing premium valuations. The sector benefits from stable, high-volume demand. 3. Research Solutions (R&D Focused) Trend: This cluster, primarily driven by AI-powered drug discovery and bioinformatics, secured the largest amount of funding in European Digital Health in H1 2025. Valuation Impact: Valuation is tied to pipeline value and platform technology. While core MedTech multiples focus on sales, these companies are valued based on the potential of their technology to accelerate and de-risk drug and device development, attracting large M&A bids from Pharma/Biotech. 4. Enterprise Value vs. Buyer Type A crucial factor is the type of buyer: Private Equity (PE): PE firms, with significant unallocated capital ("dry powder"), are paying a premium for stable, cash-flowing assets. PE transactions in European Healthcare averaged an 11.2x median EV/EBITDA multiple in the first half of 2025. Corporate Acquirers (Strategic): Corporate buyers are typically paying slightly lower multiples, averaging around 8.5x median EV/EBITDA, as they can justify a lower price by accounting for expected cost and revenue synergies. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Strategic Deployment in European HealthTech: Private Equity Roll Up Strategies in Forgotten Mid Tier Opportunities Executive Summary: The Strategic Case for Mid-Market Consolidation in European HealthTech The current European HealthTech and MedTech landscape presents a compelling and timely opportunity for specialised Private Equity (PE) deployment, driven by a simultaneous market correction and entrenched structural fragmentation. Following the "exuberance" and peak valuations of the COVID-19-driven Venture Capital (VC) boom of 2021–2022, a significant shift in investor sentiment has occurred. High interest rates and inflation have elevated the cost of capital, forcing investors to prioritise proven profitability over rapid, loss-making growth.This "flight to quality" has concentrated VC funding into a few high-conviction ventures (mega-deals), leaving a broad swathe of the mid-tier market struggling to secure necessary follow-on financing, frequently resulting in "down rounds" or seeking distressed mergers and acquisitions (M&A). This distress is amplified by Europe’s inherently fragmented healthcare structure, where complex, localised reimbursement and regulatory systems impede the organic scaling of Small and Medium-sized Enterprises (SMEs) Private equity firms are uniquely positioned to exploit this structural inefficiency through the strategic execution of a “buy-and-build” roll-up strategy. This approach focuses on acquiring cash-flow-positive, stable companies at advantageous entry multiples, often lower than comparable assets in the United States and achieving scalable value by imposing operational standardization and centralised technology integration (Tech-Enablement). The value creation thesis is centered not merely on financial arbitrage but on operational alpha, as successful buy-and-build deals significantly outperform standalone PE transactions, offering an average Internal Rate of Return (IRR) of 31.6% compared to 23.1%. This outperformance is fundamentally tied to driving measurable EBITDA growth through centralised functions, technology infusion (particularly AI), and efficient navigation of the regulatory environment. Critically, the burdensome transition to the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) creates severe "structural problems" for smaller players. For PE platforms, the cost and complexity of compliance can be converted into a proprietary, centralised moat. By acquiring companies struggling with regulatory overhead and centralising the Quality Management System (QMS) and expertise, the consolidated entity transforms a market-wide risk into a highly defensible operational advantage, justifying a valuation premium upon exit. The strategic focus must therefore be on fragmented, essential services, Diagnostics, Niche IT, and Outsourced Clinical Services where regulatory complexity acts as a filter, clearing the field for well-capitalised, operationally mature platforms. Market Dynamics and the Mid-Tier Opportunity Set The Post-VC Correction: A Valuation Reset for Strategic Buyers The macroeconomic environment has fundamentally recalibrated the European HealthTech market. The post-pandemic “exuberance” has evaporated, replaced by caution, driven primarily by high interest rates and persistent inflation that have drastically increased the cost of capital. Investors have shifted away from prioritising growth at all costs toward demanding a clear path to profitability and strong unit economics. This reorientation has channeled capital into a "selective scale" model, favouring high-conviction mega-deals. This concentration has, in turn, produced a robust supply of mid-market assets facing a funding drought. Many companies that raised capital at peak 2021 valuations are now facing valuation mismatches, unable to secure follow-on funding, resulting in a supply of attractive targets seeking distressed M&A. The subdued Initial Public Offering (IPO) market poses a continued challenge for larger private equity-backed companies and VCs seeking exits. Consequently, M&A activity, encompassing strategic acquisitions and venture-to-venture consolidation, has emerged as the primary volume pathway for liquidity. This dynamic led to a substantial spike in sponsor buyout deals in European healthcare, surging by 276% year-to-date in June 2025 compared to the previous year. For private equity firms, the target bracket generally involves stable businesses with demonstrable cash flows. Companies with earnings before interest, taxes, depreciation, and amortisation (EBITDA) in the $5M–$10M range are highly desirable, where average MedTech multiples trade between 8.4x and 10.4x EBITDA. Targets commanding premium valuations, often 5.5x to 7x revenue multiples, possess a high percentage of recurring revenue, such as Software-as-a-Service (SaaS) models, and high gross margins, particularly those providing value-based care or analytics solutions. Specialised investors, such as GHO Capital, focus specifically on investing in mid-market healthcare companies across Europe with the explicit goal of building global leaders. The European Structural Advantage: Fragmented Ecosystems European fragmentation, traditionally viewed as a barrier to scaling, is now the central thesis for PE value creation through consolidation. Europe’s healthcare landscape is a "patchwork" of diverse regulatory and reimbursement frameworks, contrasting sharply with the unified system of the United States. This complexity stifles the organic, cross-border growth of individual SMEs but offers private equity firms a unique mechanism for value creation: acquiring local champions and standardising their operations into a single, efficient, pan-European platform. The targeted "forgotten" profile consists of companies that are profitable and cash-flowing but critically lack the capital, technological sophistication (such as AI adoption), or regulatory expertise necessary to navigate international expansion. These businesses are often overlooked by large global strategics due to their localised focus or relatively small size. The successful PE strategy exploits the fundamental valuation gap between Europe and the US. European companies often trade at lower valuations compared to their US counterparts, partially due to the US having the deepest capital markets and a historically more favorable exit environment. Private equity funds can acquire European assets at lower entry multiples, rigorously standardise operations for cost efficiency, integrate modern technology like AI to enhance margins, and subsequently achieve an exit to a global strategic buyer (frequently US-based) at a higher comparative multiple. This strategic arbitrage generates significant alpha, provided the PE owner successfully delivers measured EBITDA improvement, emphasising that operational improvements are now essential for portfolio performance. The convergence of economic distress and structural fragmentation has created a unique window. The distress provides the assets, and the fragmentation provides the operational roadmap for value creation. Identifying Mid-Tier Opportunity Sub-Sectors The current strategic focus has moved away from speculative B2C digital health toward fragmented B2B infrastructure and critical clinical services, characterized by stable, recurring revenue streams. The following sub-sectors exhibit the ideal combination of fragmentation, structural importance, and vulnerability to regulatory burden that facilitates PE roll-up strategies. Specialised Diagnostics and In Vitro Devices (IVD) The European in vitro diagnostic industry is a significant market, estimated at approximately €11 billion. This market is characterised by extreme fragmentation: 95% of the industry comprises small and medium-sized enterprises (SMEs). This concentration of independent, smaller players makes it an ideal environment for a roll-up strategy focused on achieving immediate economies of scale and centralised compliance. Strategic targets within this sector include companies offering advanced diagnostics, such as genetic testing and liquid biopsies. The Laboratory Developed Tests (LDT) market in Europe, driven by rapid technological advancements, is currently in an accelerating growth phase. The value proposition for private equity is to acquire multiple local, specialised testing laboratories or IVD software developers and standardise operations. By centralising procurement, maximizing shared reference lab capacity, and integrating rigorous IVDR compliance protocols across the portfolio, the scaled entity gains the ability to compete effectively for larger public and private tenders that currently favor established large players. Niche Medical Device Components and OEMs Niche Original Equipment Manufacturers (OEMs) that specialise in proprietary, technically differentiated medical devices or high-value components present another compelling area for consolidation. These assets are typically protected by high technical barriers to entry and often generate stable, recurring service and maintenance revenue streams. Value creation in this segment hinges on achieving operational integration and excellence. PE firms focus on imposing standardised manufacturing and supply chain processes across acquired entities.Operational consulting support focusing on M&A strategy and integration, including manufacturing and development expertise, has historically delivered significant results, with demonstrable improvements in earnings before interest, taxes, depreciation and amortisation (EBITDA) of up to 20% for medical device services providers. A crucial trend in MedTech is the shift from traditional one-off product sales to service-based models. PE investment should prioritise targets capable of transitioning their business model to offer recurring revenue services, such as software maintenance, remote monitoring subscriptions, or outsourced testing agreements.Platform scale facilitates the negotiation of long-term service contracts, driving the multiple expansion associated with Software-as-a-Service (SaaS) models. Outsourced Clinical Services and Specialty Practices (IT-Enabled) The model of consolidating fragmented specialty service providers (eg. dental clinics, radiology centres, home healthcare) has been successfully deployed, particularly in the DACH region and Nordic markets. This strategy benefits from the ongoing shift toward delivering health and social care in more effective, efficient ways, often in non-acute or post-acute settings. Case studies validate this approach. Cera Health, a London-based company, expands into new locations by acquiring existing home healthcare companies often small family businesses and immediately rolls out its proprietary patient management software to standardise service delivery, optimise efficiency, and centralise billing. Similarly, PE activity in the DACH region targets service providers like dental practices, which are amalgamated into large networks (e.g., Nordic Capital’s European Dental Group) to streamline operations and centralise administrative functions. An emerging, highly attractive vertical is specialised support services, including Contract Development and Manufacturing Organisations (CDMOs) and outsourced clinical services (radiology, pathology, catheterisation). These services provide recurrent revenue streams and allow public and private providers to reduce burdensome capital costs by outsourcing specialist functions. The structural opportunity across these sub-sectors is best summarised by their inherent fragmentation and the resultant potential for standardised value creation: Table I: European HealthTech Mid-Tier Buy-and-Build Attractiveness Matrix Sub-Sector Focus Fragmentation Level Recurrent Revenue Potential Primary Value Creation Lever Key Regulatory Headwind Specialised Diagnostics (IVD/LDT) Very High (95% SMEs) Medium-High (Testing volume) Operational Standardisation, Commercial Scale IVDR Compliance Complexity Outsourced Clinical Services Very High (Local/National) High (Contract/Subscription) Centralised IT & Billing, Cross-Selling Local Reimbursement Patchwork Niche MedTech/Device OEMs Medium-High (Proprietary tech) Medium (Service/Maintenance contracts) Supply Chain Optimisation, Operational Efficiency (20% EBITDA uplift) MDR Compliance Burden Interoperability & Data IT Medium (Specialied providers) Very High (SaaS Model) EHDS Data Monetisation, AI Integration GDPR/EHDS Compliance & Security The Private Equity Roll-up Playbook: Execution and Phasing Successful execution of the buy-and-build strategy demands a rigorous, phased approach, moving beyond simple financial engineering to focus on deep operational and technological integration. Platform Acquisition and Scaling Strategy The acquisition of the initial platform company is the foundation of the strategy. This platform must exhibit a clear path to profitability, possess robust clinical and commercial validation, and maintain a demonstrable track record of compliance with GDPR and formal Quality Management Systems (QMS). Ideally, the platform should have a recurring, scalable revenue base and be "technology-enabled" from the outset, enabling immediate digital transformation across subsequent bolt-ons. The methodology involves acquiring the platform, followed by executing a series of smaller, strategic "bolt-on" acquisitions to build scale. This creates economies of scale, allowing the consolidated entity to better compete against larger players. Integration strategies can involve either horizontal expansion (scaling geographically or expanding service lines) or vertical integration (acquiring entities along the supply chain, such as laboratories for a clinic group). While vertical integration can be powerful, it requires a clear strategic foundation to ensure that the integrated function aligns with the core competency and does not undermine the value proposition. Crucially, clear communication regarding how the central entity adds operational or commercial value to the acquired local practices is necessary to avoid alienating practitioner owners. Phased Integration and the First 100 Days The execution of the roll-up must follow a disciplined, rapid integration timeline, segmented into Pre-close (30–60 days), Day 1 (Immediate), First 100 Days (3–4 months), and Long-term (6–12+ months) phases. The immediate priorities on Day 1 and during the First 100 Days are centralisation and standardisation. System integration and cost reduction are paramount. The most reliable method for margin enhancement is realising cost synergies through consolidating back-office functions - Finance, Human Resources, Information Technology and Procurement, across the newly formed entity. Centralisation is also essential for integrating regulatory compliance. For instance, companies like Cera Health immediately roll out their proprietary patient management software to all acquired entities, standardising operations from the start. A frequently overlooked activity that carries significant execution risk is cultural alignment. Since many mid-market targets are small family businesses or practices managed by founding physicians, preserving the unique value proposition offered by practitioner owners is critical. The long-term success of the roll-up depends on successful culture alignment and clearly defining what is centralised (administration, compliance) versus what remains decentralised (clinical care). Navigating Regional and Regulatory Heterogeneity The defining structural complexity of the European market is its regulatory and reimbursement diversity. This complexity is not merely an obstacle but a powerful market force that accelerates consolidation. The European regulatory burden, particularly the transition to MDR and IVDR, is widely viewed as a "significant structural headwind". The complexity, cost, and slow process create substantial challenges for SMEs, which often lack the financial resources or internal expertise to meet the demands for dual-certification (MDR combined with the impending AI Act). This regulatory friction increases the supply of smaller, high-quality MedTech and IVD assets that are willing to sell to a larger platform capable of absorbing and managing this regulatory risk centrally. The successful execution of a cross-border roll-up therefore relies heavily on operationalizing stringent, universal compliance standards (GDPR, QMS) across all acquired entities. Market access and reimbursement systems are similarly fragmented. Central and Eastern European (CEE) countries often feature centralised systems with a single main buyer (National Health Insurance), yet face obstacles from outdated legislation. In contrast, expansion into markets like Germany requires navigating negotiations with numerous healthcare insurers, while the UK operates on a strict, evidence-based model demanding extensive documentation. To mitigate these risks and scale successfully, the PE platform must adopt a specialized strategy for cross-border market access. This involves developing region-specific roadmaps and utilising "translators", local experts who possess deep knowledge of specific European systems and can bridge the gap between technical R&D and commercial market entry, advising on comparable medical products and optimal reimbursement pathways. Critical Value Creation Levers and Financial Returns In the current macro-environment, where easy returns from market multiple expansion are scarce, value creation must be driven predominantly by outperforming competitors on EBITDA growth and operational improvements. Leveraging Technology for Margin Expansion Technology integration is the primary mechanism for driving efficiency and creating a defensible competitive advantage. Private equity firms are actively "infusing technology, particularly AI, into these acquired businesses to drive efficiency and margin improvements". Artificial Intelligence (AI) stands out as the single most powerful driver of valuation premiums, attracting 65% of total digital health funding in the first half of 2025. PE platforms must prioritise assets with proprietary AI algorithms and clinically validated solutions, integrating these tools deeply into existing clinical and administrative workflows. Operational digitisation, particularly the centralisation of back-office functions, is essential. Shared platforms should deploy tools such as AI-assisted scheduling, analytics, and billing automation to streamline operations and reduce administrative overhead. Furthermore, the new European Health Data Space (EHDS) is foundational for long-term value creation. The EHDS, now enforced under Regulation (EU) 2025/327, introduces a harmonised technical, legal, and governance architecture for the secure secondary use of electronic health data across the EU. While GDPR historically presented high data handling risks, the EHDS provides the framework to ethically and effectively leverage aggregated patient data for analytics and research. Firms capable of ensuring interoperability and secure data integration with Electronic Health Records (EHRs) command higher revenue multiples, typically ranging from 5.5x to 7x. Therefore, the PE platform must prioritise "data plumbing", the technical infrastructure necessary to securely aggregate and synthesise data from all bolt-ons, transitioning the consolidated entity into a unified, data-driven analytics powerhouse that qualifies for the premium valuations associated with AI and analytics companies. Operational Excellence and Synergy Realisation Value creation in the buy-and-build model is realized through two key synergy streams: cost and revenue. Traditional cost synergies involve consolidating back-office functions (finance, HR, IT, legal). More specialised opportunities exist in supply chain optimisation. By moving from relying on local distributors within each fragmented business to centralised, direct international sourcing, platforms can leverage their scale to renegotiate pricing and generate substantial cost reduction, as validated by specialised operational due diligence. Revenue synergies are realised through cross-selling and commercial excellence. The newly centralised platform provides a unified network for introducing additional products or services across the acquired customer base. For instance, a consolidated group of diagnostic or medical practices can rapidly roll out specialised ancillary services or proprietary digital therapeutics to all patients, a highly effective strategy demonstrated in the consolidation of fragmented service sectors. Moreover, PE focus on enhancing sales and marketing strategies across the portfolio ensures that growth is accelerated beyond the capability of the independent, localised firms. Strategic Deployment in European HealthTech: Private Equity Roll Up Strategies in Forgotten Mid Tier Opportunities Valuation Frameworks for PE HealthTech M&A The entry and exit strategy is underpinned by established valuation multiples, which confirm the value potential when operational excellence is achieved. For general HealthTech, the average revenue multiple is typically between 4x and 6x. However, companies within the premium segment, those with proprietary AI algorithms, scaled telehealth platforms, or advanced analytics, command higher valuations, often 6x to 8x revenue or more. Similarly, data-driven companies specializing in actionable data and interoperability command multiples of 5.5x to 7x. For cash-flow positive mid-market businesses, specifically those with EBITDA in the target $5M–$10M range, multiples are robust. MedTech assets typically trade between 8.3x and 10.4x EBITDA, while Healthcare IT assets fall slightly lower, around 7.2x to 8.8x EBITDA. This premium valuation associated with technology and stability validates the necessity of the operational strategy. The successful performance of the overall buy-and-build strategy is statistically validated: B&B deals deliver an average Internal Rate of Return (IRR) of 31.6%, a significant premium over the 23.1% IRR achieved by standalone PE deals. This performance differential reinforces that active operational management and structural consolidation are the fundamental drivers of outsized returns. Illustrative HealthTech M&A Valuation Benchmarks (Mid-Market EBITDA Range) HealthTech Segment (Proxy) Target EBITDA Range Average EBITDA Multiple Average Revenue Multiple (Premium Tech) Key Driver of Premium Medical Devices (Niche/MedTech) $5M-$10M 8.3x - 10.4x 4.4x - 5.0x Proprietary Product/Technical Differentiation Data-Driven/Analytics HealthTech N/A (Premium Segment) > 10.0x (Implied) 6.0x - 8.0x Clinically validated AI/Proprietary Algorithms, EHDS Readiness Healthcare IT (Practice Mgmt/SaaS) $5M-$10M 7.2x - 8.8x 4.0x - 5.5x High Recurrent Revenue, Scalability, Strong Unit Economics Specialised Clinical Services $5M-$10M 7.1x - 9.7x 3.3x - 4.1x Stability, Consolidation Potential, Non-Acute Shift Roll-up Implementation Roadmap: Operational Excellence Focus PE Phase Target Timeframe Primary Focus (Value Creation Lever) Critical Operational Activities Platform Acquisition (Pre-Close) 30–60 Days Strategic/Financial Alignment Deep regulatory & IP diligence; Define Central Operating Model (COM); Secure financing. Rapid Integration (Day 1 - 100) 3–4 Months Cost Reduction & Standardisation (Back-Office) Centralise Finance, HR, and Procurement ; Deploy universal QMS and GDPR/EHDS standards. Acceleration & Optimization 6–12+ Months Growth, Cross-Selling, and Tech Integration Implement shared technology (AI tools, billing automation); Develop region-specific reimbursement pathways; Drive commercial cross-selling. Conclusion and Forward-Looking Recommendations Strategic Outlook and Investment Trajectory The European healthcare technology sector is experiencing a sustained, dynamic M&A environment throughout 2025, with strong signals indicating continued momentum extending into 2026. This recovery is characterised by a "cautious yet discernible rebound" and a strong focus on profitable, proven business models. Underlying drivers, including pervasive digital transformation, the shift toward value-based care, and the necessity to build scale for AI adoption, are stimulating significant activity. European assets are drawing increased interest from global investors, particularly those based in Asia and the US, due to attractive relative valuations compared to the US market and the underlying economic stability of the region. This cross-border capital inflow is expected to intensify competition for high-quality, platform-ready assets. High-Conviction Recommendations The analysis dictates a targeted strategic playbook for capital deployment in the European mid-tier: Prioritise Technology-Enabled Services Platforms: The core strategy should focus on establishing platforms in B2B Health IT, particularly systems that manage core administrative and clinical workflows (eg. patient management software, billing automation). These platforms should then be used as the centralised operating engine to roll up specialised, fragmented clinical services, such as outsourced diagnostics, post-acute care, or specialty medical practices. This approach ensures high recurring revenue and maximises the efficiency gains from centralisation. Make AI and Data Interoperability a Capital Imperative: Dedicate significant capital expenditure post-acquisition to integrating standardised, proprietary software systems across the bolt-ons. This is the crucial step where the platform infuses technology to drive essential margin improvements. Specifically, the platform must be engineered to comply with the EHDS framework, ensuring the aggregated data is secure, interoperable, and capable of supporting advanced analytics, thereby commanding the highest possible exit multiples. Centralise Regulatory Expertise as a Core Service: Given the complexity of MDR/IVDR and the fragmented reimbursement systems, the platform must treat regulatory compliance as a centralised, value-added service. This expertise acts as a proprietary shield, reducing risk across the portfolio and enabling the scaled entity to successfully navigate local market access hurdles that proved insurmountable for the acquired SMEs. Mitigating Regulatory and Antitrust Risk As the PE roll-up strategy becomes increasingly common across Europe, the potential for regulatory and antitrust scrutiny is rising, mirroring recent enforcement trends in the US. Private equity firms must proactively mitigate this risk by undertaking deeper antitrust analyses, factoring in geographic concentration, and ensuring due diligence covers the long-term competitive landscape. The value justification for consolidation must be clearly articulated beyond mere cost reduction. While mergers are often essential for SMEs to gain the scale and resources needed to bring medical innovation to market, consolidation must demonstrate a verifiable improvement in patient outcomes (eg. quality standardisation, improved access, or cost savings) to defend against potential policy actions aimed at counteracting market control. The alignment of the consolidated platform with the long-term policy goals of European digitalisation (EHDS) and the shift to value-based care provides the strongest defense against regulatory intervention. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Exec Summary: Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity firms that are looking for companies with the potential for double-digit growth. Some of the benefits of investing in midtier healthtech companies include: Lower risk: Midtier healthtech companies are less likely to fail than the largest healthtech companies. This is because they have already demonstrated a proof of concept and have won flagship customers. Double-digit growth: Midtier healthtech companies have the potential for double-digit growth. This is because they are still in the early stages of their development and have a lot of room to grow. Expertise: Private equity firms can bring their expertise to help midtier healthtech companies scale and grow. This can include providing access to capital, strategic guidance, and operational support. Here are some of the most likely private equity rollup plays in the 'Forgotten MidTier' across the HealthTech landscape: Telehealth: The telehealth market is highly fragmented, with a large number of small, independent providers. This makes it ripe for consolidation, as private equity firms can acquire these companies and create larger, more efficient platforms. Health IT: The health IT market is also fragmented, with a wide range of companies providing different solutions. Private equity firms can acquire these companies and create one-stop shops for health IT solutions. eCommerce in healthcare: The e-commerce market in healthcare is growing rapidly, as more and more people are using online platforms to purchase healthcare products and services. Private equity firms can acquire e-commerce companies in healthcare and help them to expand their reach and grow their market share. Behavioural health: The behavioural health market is also ripe for consolidation, as there are a large number of small, independent providers. Private equity firms can acquire these companies and create larger, more integrated behavioural health platforms. Digital therapeutics: Digital therapeutics is a rapidly growing field, as more and more companies are developing software-based treatments for a variety of medical conditions. Private equity firms can acquire digital therapeutics companies and help them to scale their operations and reach more patients. Pharmaceuticals: The pharmaceutical market is also a potential target for private equity rollups. Private equity firms could acquire small, innovative pharmaceutical companies and merge them together to create larger, more diversified pharmaceutical companies. Medical devices: The medical devices market is another potential target for private equity rollups. Private equity firms could acquire small, innovative medical device companies and merge them together to create larger, more diversified medical device companies. These are just a few of the most likely private equity rollup plays in healthtech. As the healthcare industry continues to evolve, we can expect to see more and more consolidation in this space. What is a private equity rollup strategy? A private equity rollup is a strategy used by private equity firms to acquire a number of smaller companies in the same industry and merge them together to create a larger, more diversified company. This strategy is often used in fragmented industries where there are a large number of small, independent players. By acquiring these companies, private equity firms can achieve economies of scale, reduce costs, and increase market share. There are a number of benefits to using a private equity rollup strategy. First, it can allow private equity firms to achieve economies of scale. By merging together a number of smaller companies, private equity firms can reduce costs in areas such as marketing, sales, and administration. Second, a private equity rollup can allow private equity firms to increase market share. By acquiring a number of smaller companies, private equity firms can become a larger player in the industry and gain a competitive advantage. Third, a private equity rollup can allow private equity firms to create a more diversified company. By merging together a number of companies in different segments of the industry, private equity firms can reduce their risk exposure. However, there are also some risks associated with using a private equity rollup strategy. First, it can be difficult to integrate a number of different companies into a single entity. This can lead to operational problems and culture clashes. Second, a private equity rollup can be expensive. Private equity firms often have to pay a premium to acquire smaller companies. Third, a private equity rollup can take a long time to complete. This can be a problem if the industry is changing rapidly. Overall, a private equity rollup can be a successful strategy for creating a larger, more diversified company. However, it is important to weigh the benefits and risks before pursuing this strategy. Private Equity $15 Billion Funds for Healthcare According to a report by Bain & Company, firms raised more than $15 billion in new buyout capital for funds where healthcare is the exclusive or core focus in 2022. This is the highest level of fundraising for healthcare-focused private equity funds since 2019. There are a number of factors that are driving this trend. First, the healthcare industry is undergoing a period of rapid change, as new technologies and business models are emerging. This is creating opportunities for private equity firms to invest in companies that are leading the way in innovation. Second, the healthcare industry is a large and growing market. The global healthcare market is expected to reach $10 trillion by 2025. This provides private equity firms with a large pool of potential investment opportunities. Third, there is a strong demand for private equity investment in healthcare. Institutional investors, such as pension funds and insurance companies, are increasingly looking to private equity as a way to generate high returns. As a result of these factors, we can expect to see continued growth in private equity investment in healthcare in the years to come. Here are some of the specific areas of healthcare that are seeing the most private equity investment: Digital health: Private equity firms are investing in digital health companies that are developing new technologies to improve the delivery of healthcare. This includes companies that are developing telehealth solutions, electronic health records, and other software-based solutions. Life sciences: Private equity firms are investing in life sciences companies that are developing new drugs, diagnostics, and medical devices. This includes companies that are working on treatments for cancer, Alzheimer's disease, and other chronic diseases. Healthcare services: Private equity firms are investing in healthcare services companies that provide support services to hospitals, doctors' offices, and other healthcare providers. This includes companies that provide staffing, IT services, and other support services. These are just a few of the many areas of healthcare that are seeing private equity investment. As the healthcare industry continues to evolve, we can expect to see even more investment in this sector in the years to come. Forgotten midtier opportunities across the HealthTech landscape Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity firms that are looking for companies with the potential for double-digit growth. The healthcare technology (healthtech) industry is vast and growing, with a wide range of companies at different stages of development. Private equity firms have traditionally focused on investing in the largest and most well-known healthtech companies, such as those that have achieved unicorn status. However, there is a growing opportunity for private equity firms to invest in the midtier of the healthtech landscape. Some of the benefits of investing in midtier healthtech companies include: Lower risk: Midtier healthtech companies are less likely to fail than the largest healthtech companies. This is because they have already demonstrated a proof of concept and have won flagship customers. Double-digit growth: Midtier healthtech companies have the potential for double-digit growth. This is because they are still in the early stages of their development and have a lot of room to grow. Expertise: Private equity firms can bring their expertise to help midtier healthtech companies scale and grow. This can include providing access to capital, strategic guidance, and operational support. Some of the challenges of investing in midtier healthtech companies include: Competition: The midtier healthtech landscape is becoming increasingly competitive. This is because there are more and more companies vying for a share of the market. Regulation: The healthcare industry is highly regulated. This can make it difficult for midtier healthtech companies to navigate the regulatory landscape. Exit: There are fewer potential buyers for midtier healthtech companies than for larger companies. This can make it difficult for private equity firms to exit their investments. Overall, there is a growing opportunity for private equity firms to invest in the midtier of the healthtech landscape. These companies offer the potential for double-digit growth with a lower risk profile than the largest healthtech companies. However, there are also some challenges that private equity firms need to be aware of, such as competition and regulation. Here are some examples of midtier healthtech companies that have been successful: Catalyst Health: Catalyst Health is a provider of telehealth services. The company has raised over $100 million in funding and has over 1 million patients. Athenahealth: Athenahealth is a provider of electronic health records (EHR) software. The company has raised over $2 billion in funding and has over 100,000 customers. PatientPing: PatientPing is a provider of patient engagement software. The company has raised over $50 million in funding and has over 10,000 customers. These companies have all demonstrated the potential for growth and success in the midtier of the healthtech landscape. Private equity firms that are looking for opportunities in the healthcare industry should consider investing in these types of companies. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

NHS England Medium Term Planning Framework 2026/27–2028/29: Strategic Implications, Operational Mandates and the Financial Feasibility of Reform Executive Summary: Synthesis of the Three-Year Mandate The NHS England Medium Term Planning Framework (MTPF), officially published on 24 October 2025, establishes the operational and financial roadmap for Integrated Care Boards (ICBs) and providers for the three-year period spanning 2026/27 to 2028/29. This document represents a fundamental shift away from the legacy of crisis-driven, short-term annual planning toward a medium-to-long term system designed to foster local innovation and support long-term sustainability. The MTPF is designed as the critical link, bridging the immediate pressures faced during recovery with the deeper, systemic reform required for the National Health Service (NHS). Core Principles and Alignment with the 10-Year Health Plan (10YHP) The framework is predicated on accelerating the strategic objectives set out in the 10 Year Health Plan for England (10YHP), which articulated three foundational shifts for system transformation. These shifts are central to all mandated planning activities across the MTPF period. : From Treatment to Prevention: Emphasis is placed on primary and secondary prevention, including supporting preventative care through the GP contract and locally agreed delivery plans for screening and vaccination, aligning with approaches such as Core20PLUS5. From Analogue to Digital: Full utilisation of digital tools and infrastructure is mandated to drive efficiency, standardise care, and improve patient experience. From Hospital to Community: This necessitates the aggressive development of Neighbourhood Health Service models to reduce demand on acute services and enable care to be delivered closer to home. The Recovery/Reform Dual Imperative The MTPF is arguably the most ambitious plan published in a generation, aiming not just for incremental improvement but for a complete restoration of constitutional performance standards by 2028/29. Its successful implementation hinges on achieving unprecedented operational improvements alongside simultaneous, complex systemic reforms. The publication timing in October 2025 provides significantly more lead time for local leaders to construct robust multi-year integrated plans, contrasting sharply with previous annual cycles. However, this longer planning cycle does not mitigate the scale of the required transformation, which includes structural changes to commissioning and primary care models. Key Findings and High-Level Recommendations The analysis of the MTPF highlights critical structural dependencies and inherent financial risk. Despite a positive multi-year financial settlement from Spending Review 2025 (SR25), the framework mandates that all ICBs and providers must achieve financial balance or surplus, underpinned by a highly challenging 2 per cent annual productivity gain. This productivity requirement is essential for reversing the trend of workforce growth outpacing activity growth post-2019/20. The successful delivery of the MTPF is thus fundamentally tied to the ability of ICBs to rapidly and effectively implement the Neighbourhood Health Service models, the primary mechanism for demand reduction, thereby creating the necessary margin to meet the stringent financial mandates without compromising quality or safety. The New Architecture of NHS Planning and Governance Transition from Annual Cycles to Medium-Term Planning (2026/27–2028/29) The MTPF sets targets and requirements for NHS organisations over the next three and five years, marking a deliberate move away from short-term planning. The three-year planning cycle (2026/27 to 2028/29) is enabled by the corresponding three-year revenue and four-year capital settlement confirmed during Spending Review 2025. This framework is explicitly designed to unleash the ambition of local teams and provide a platform for NHS leaders to drive necessary change. The operational planning guidance for 2025/26, published in January 2025, served as the initial step, demanding aggressive recovery and efficiency (eg. 4% savings); the MTPF now extends these pressures into structural reform over the medium term. The framework attempts to streamline national direction by reducing the number of headline success measures to 15 over the three-year period, down from 18 in the 2025/26 guidance and 133 in 2022/23. This welcome focus is intended to allow local leaders greater clarity and agency in resource allocation. However, the commitment to publish at least 20 additional guidance and resource documents in the following months, covering areas from neighbourhood health to integrated health organisations, signifies significant central direction that will shape local plan execution. Devolved Accountability and Central Direction The MTPF emphasises greater devolution of funding and decision-making to systems, removing most ring-fences to allow local leaders to innovate and use scarce resources effectively. Correspondingly, the NHS Oversight Framework requires ICBs and providers to focus intensely on performance areas like finance, urgent and emergency care, elective, and mental health. While ICBs are currently not segmented due to significant changes undertaken, provider capability assessment and performance management (tiering) activities will continue to be undertaken by NHS England regional teams for underperforming organisations. A close examination of the framework reveals a nuanced strategy: while the rhetoric supports local empowerment, the mechanisms of delivery are heavily dictated by centrally defined blueprints. This means local leaders are delegated the responsibility for difficult implementation decisions and financial risk management, but the core architectural design of system change remains tightly controlled via prescriptive guidance such as the Strategic Commissioning Framework and the Model Neighbourhood Framework. For local systems, success hinges on skillfully adapting and executing these prescribed models, not on creating fundamentally divergent local strategies. Structural Guidance: Strategic Commissioning and Delegated Responsibilities Fundamental structural changes to commissioning are mandated through the MTPF. The Strategic Commissioning Framework (SCF) was published in October 2025, providing ICBs with a clear scope for their evolved role and building upon the Model ICB blueprint. ICBs are required to implement this SCF as part of their shift toward multi-year planning. A major functional shift is the delegated commissioning responsibility for vaccination and screening services, which will move from NHS England to ICBs, likely from April 2027, subject to the passage of necessary legislation. In preparation, NHS England will develop a new commissioning and contracting framework in 2026/27. This shift is strategically linked to increasing prevention and access; for example, NHS England will enable community pharmacy to deliver vaccinations off-premises where commissioned, subject to regulatory approval, leveraging primary care assets to drive preventative goals. Further governance models are anticipated later in 2025, including a draft foundation trust framework released for consultation in November and a Model Integrated Health Organisation (IHO) framework. Concurrently, a new Management and Leadership Framework is expected in autumn 2025 to set standards and competencies for leaders across five levels. Timeline of Key MTPF Implementation Guidance and Policy Shifts Guidance/Framework Expected Publication/Implementation Date Impact and System Requirement Source Medium Term Planning Framework (MTPF) 24 October 2025 (Published) Sets targets and requirements for 2026/27 to 2028/29. NHS Strategic Commissioning Framework October 2025 ICBs to implement; forms basis for their evolved commissioning role. NHS Technical Guidance: Multi-Year Revenue and Capital Allocations Autumn 2025 Provides details on financial assumptions and funding levels. NHS Draft Foundation Trust Framework November 2025 (For consultation) Outlines standards and governance for Foundation Trusts. NHS Model Neighbourhood Framework Expected November 2025 Sets foundations for scaling community-based care models. NHS New Management and Leadership Framework Autumn 2025 Sets standards and competencies for clinical and non-clinical leaders. NHS Delegated Commissioning of Vaccination/Screening Likely April 2027 (Subject to legislation) Full shift of commissioning responsibility to ICBs. NHS Financial Discipline and the Productivity Imperative Analysis of the Spending Review 2025 (SR25) Settlement The MTPF is framed against the backdrop of the SR25 settlement, which provides a defined multi-year financial envelope, enabling the shift away from annual planning. Revenue funding is set to increase by 3 per cent in real terms over the SR25 period, culminating in £226 billion in 2028/29. Capital spending also sees an uplift, increasing from £13.6 billion in 2025/26 to £14.6 billion in 2029, representing a 3.2 per cent real-terms increase over the period. This is supplemented by a commitment of up to £10 billion for NHS technology and digital transformation by 2028/29. However, the perceived value of this financial settlement is moderated by significant underlying cost pressures. The 2025/26 planning guidance noted that a 4 per cent nominal spending uplift would feel closer to a 2 per cent real-terms increase for most systems once specific cost pressures are accounted for. The strategic ambition of the MTPF must therefore be achieved primarily through improved efficiency rather than substantial new expenditure. The Mandate for Financial Balance and Productivity A foundational requirement of the MTPF is stringent financial discipline. All ICBs and providers are expected to deliver a balanced or surplus net system financial position in 2025/26 and subsequent years. The long-term objective is to operate without reliance on deficit support by 2029. Crucially, this financial stability is predicated upon achieving 2 per cent annual productivity gains. This requirement is intended to reverse the troubling trend where NHS workforce growth has significantly outpaced activity growth since 2019/20, a dynamic identified as unsustainable for the long-term health of the service. Furthermore, this 2% annual mandate follows the highly challenging 4 per cent efficiency savings demanded of providers in the 2025/26 operational planning guidance. ICBs and providers are explicitly asked to "close the activity/WTE gap against pre-Covid levels". The mandate for 2% sustained annual productivity gains presents the most significant structural risk to the MTPF. Historical data suggests providers achieved an average of only 0.9% efficiency gains per year in the decade preceding the pandemic. Successfully achieving a rate more than double this historical average requires profound, systemic, and recurrent savings, which must be realised quickly from the structural reforms outlined, particularly the shift to digital and community-based care. If these reforms yield slow benefits, systems will face intense pressure to rely on non-recurrent cost improvement programmes (CIPs), which may compromise long-term quality and recovery efforts. Expenditure Management and Waste Reduction To support financial balance, the MTPF reiterates a forceful mandate to reduce waste, most prominently through expenditure control. ICBs and systems must reduce agency expenditure as far as possible, with a minimum required reduction of 30% on current spending across all systems. This reduction is critical to ensuring savings are directed back into frontline services. Providers are directed to improve operational and clinical productivity through targeted initiatives.These include optimising medicines value, reducing unwarranted variation in prescribing through implementation of Low Value Prescribing Guidance, and maximising the use of best value biological medicines where bio-similars are available. Furthermore, trusts are expected to optimise energy value through green plans and utilise the new national contract developed with Crown Commercial Services for energy procurement. These measures are integral to achieving the required efficiency factor and living within the allocated budget. Medium Term Planning Financial Mandates and Spending Review (SR25) Commitments Financial Metric MTPF Expectation/Target Associated Planning Period Supporting Information Revenue Funding Increase (Real-terms) 3% increase over SR25 period Up to 2028/29 Revenue funding up to £226 billion in 2028/29 Capital Spending Increase (Real-terms) 3.2% increase over SR25 period Up to 2029 Increase from £13.6bn (2025/26) to £14.6bn (2029) Annual Productivity Mandate 2% annual productivity gains Each year of the MTPF (2026/27 onwards) Required for delivering financial balance/surplus System Financial Position Deliver a balanced net system financial position 2025/26 and subsequent years All ICBs and providers expected to deliver balance/surplus Agency Expenditure Reduction Minimum 30% reduction on current spending Across all systems (2025/26 guidance) Part of wider mandate to reduce waste Restoring Constitutional Standards: Elective, Cancer and UEC Targets The MTPF commits to ambitious escalation targets across all major constitutional standards, designed to return services to much better health by the end of the planning period. Elective Care Recovery and the RTT Trajectory The framework sets a highly accelerated trajectory for referral to treatment time (RTT) performance. Following the challenging 2025/26 target of 65% nationally, the MTPF mandates significant medium-term improvements: 2026/27 Target: The national performance target for RTT is set at 70% of patients waiting no longer than 18 weeks for treatment. Every trust is expected to contribute by delivering a minimum 7 per cent improvement in 18-week performance or achieving a minimum of 65 per cent performance, whichever is greater. 2028/29 Target: The ultimate goal is to achieve the constitutional standard that at least 92% of patients are waiting 18 weeks or less for treatment. This ambition is supported by the goal of achieving 2.5 million fewer patients waiting more than 18 weeks by March 2029. Furthermore, systems must continue the immediate focus on eliminating the longest waits. The proportion of people waiting over 52 weeks for treatment must be reduced to less than 1% of the total waiting list by March 2026. Cancer Standards: Faster Diagnosis and Treatment Performance against cancer constitutional standards remains a core priority. Improvement strategies focus on maximising care for low-risk patients in non-cancer settings and improving productivity within cancer pathways. Faster Diagnosis Standard (FDS): Performance against the 28-day FDS must be maintained at the new threshold of 80% throughout the MTPF period. Treatment Standards: By March 2027, every trust is required to deliver 94 per cent performance for 31-day standards and 80 per cent performance for 62-day standards. This builds significantly on the 2025/26 operational target, which aimed for 75% for the 62-day standard by March 2026. Urgent and Emergency Care (UEC) Improvement Performance targets for UEC are closely linked to patient flow initiatives derived from the shift to community care. Following the 2025/26 operational target of a minimum of 78% of patients seen, admitted, discharged, or transferred from Emergency Departments within four hours, the MTPF escalates this requirement: every trust must maintain or improve performance to 82 per cent by March 2027. Ambulance performance is targeted by improving Category 2 ambulance response times to an average of 30 minutes across 2025/26. Local plans must show how systems will meet the maximum 45-minute ambulance handover time standard, improve flow, and eliminate corridor care, with a particular focus on reducing 12-hour waits. For diagnostics, every system must deliver a minimum 3 per cent improvement in performance against the DM01 diagnostics 6-week wait standard (or 20 per cent performance, whichever is greater) to move toward the national objective of no more than 14 per cent waiting over six weeks. The rapid escalation of these performance target, particularly the trajectory toward 92% RTT, creates a profound operational challenge, especially when coupled with the mandated financial efficiency. The ability of the NHS to meet these ambitious targets while simultaneously delivering 2% annual productivity gains depends entirely on the timely and effective deployment of digital tools and the Neighbourhood Health Service models. If these structural reforms fail to deliver immediate, scalable demand reduction and throughput improvements, systems will be caught between the critical demands of clinical constitutional standards and the uncompromising mandate for financial balance. Key Performance Targets: Comparison of Operational and Medium-Term Framework Goals Clinical Domain 2025/26 Operational Target (Baseline for MTPF) 2026/27 MTPF Target 2028/29 MTPF Target Elective Care (18-week RTT) 65% national target 70% national target 92% national target UEC 4-Hour Standard (A&E) Minimum 78% by March 2026 Maintain or improve to 82% by March 2027 Constitutional Standard (Implicit) Cancer 28-day Faster Diagnosis Standard (FDS) 80% by March 2026 Maintain performance at 80% Constitutional Standard (Implicit) Diagnostics (6-week wait) N/A (Focus on improvement) Minimum 3% improvement (towards 14% max wait) Constitutional Standard (Implicit) Community Health Services (18-week RTT) N/A (Focus on productivity/scaling) At least 78% of activity within 18 weeks At least 80% of activity within 18 weeks System Transformation: Community, Primary Care and Mental Health Implementing the "Hospital to Community" Shift: Neighbourhood Health Services The strategic core of the MTPF is the acceleration of the "Hospital to Community" shift through the development of Neighbourhood Health Service models. ICBs and providers are mandated to develop these models immediately to reduce demand on hospitals and prevent long and costly admissions. The forthcoming Model Neighbourhood Framework, expected in November 2025, will provide the structural blueprint for standardising and scaling key components of this care model. The initial focus for 2025/26 is on preventing people from spending unnecessary time in acute settings, particularly for adults and Children and Young People (CYP) with complex needs. The long-term vision requires strengthened primary and community-based care, reduction in avoidable long-term residential care admissions, and improved coordination with wider public services and the Voluntary, Community, and Social Enterprise (VCSFE) sector. A critical underlying assumption of the MTPF is that decentralizing care will yield cost efficiencies. However, the history of previous health plans shows that transferring care closer to home requires significant upfront investment in local infrastructure and staffing, meaning care in the community is not inherently "care on the cheap". For the Neighbourhood model to succeed in delivering both improved care and financial balance, ICBs must execute a fundamental shift in resource allocation, moving funding away from high-tariff acute provision and into community capacity before the full benefits of reduced acute demand are realised. Primary Care Access and Prevention Improved access to general practice is a key success measure, assessed through metrics such as patient experience captured by the ONS Health Insights Survey. ICBs are expected to target support to practices based on their ability to provide timely appointments and positive overall patient experience. A significant commitment in the framework is the improvement of access to urgent dental care, requiring ICBs to commission an additional 700,000 urgent dental appointments. In line with the shift from treatment to prevention, the MTPF mandates robust, locally agreed delivery plans for preventative services such as screening and vaccination, leveraging the GP contract and the expanded role of community pharmacy. The Oversight Framework reinforces this by monitoring ICB performance across key prevention metrics, including cancer screening rates, pregnant women who quit smoking, and obesity programmes. Mental Health, Learning Disabilities, and Autism Care Mental health improvement is focused on accelerating patient flow, improving productivity, and reducing reliance on inpatient settings. A core success measure is the reduction of reliance on mental health inpatient care for people with a learning disability and autistic people, with a mandated minimum 10% reduction. This is supported by specific capital allocations to reduce Out-of-Area Placements (OAPs). ICBs must ensure high-quality and accessible community infrastructure is in place, aligning with proposed Mental Health Act reform, to ensure that admissions are reserved only for assessment and treatment that definitively requires an inpatient setting. Furthermore, targets are set to increase the number of CYP accessing services to meet the national ambition of providing services to 345,000 additional CYP aged 0–25 compared to 2019 levels. The framework seeks to achieve 100 per cent coverage of Mental Health Support Teams by 2029/30. Community Health Services Capacity The MTPF introduces specific, quantifiable targets for community services, essential for supporting the Neighbourhood model and avoiding acute admissions. ICBs must proactively increase community health service capacity to manage a projected 3 per cent expected annual growth in demand. Performance metrics for community service RTTs require systems to ensure at least 78 per cent of activity occurs within 18 weeks by 2027, rising to 80 per cent by 2029, alongside a commitment to develop a plan to eliminate all 52-week waits. Productivity enhancement in community settings is also mandated, requiring the use of digital tools, the expansion of point-of-care testing, standardizing core service provision, and scaling the use of digital therapeutics, particularly for musculo-skeletal (MSK) treatment. Enablers of Change: Digital, Capital and Workforce Reform Digital Transformation: The "Analogue to Digital" Shift Digital capability is recognised as a fundamental enabler for achieving both productivity and system reform.The MTPF is backed by a substantial commitment to technology investment, contributing to the overall £10 billion allocated by 2028/29. In the next financial year, £596 million will be allocated to drive frontline digital transformation and operational capability enhancement, supplemented by a further £400 million specifically aimed at productivity-improving technology initiatives. Key digital mandates include advancing the adoption of the Federated Data Platform (FDP) and supporting the transition to fully digitised systems. Significant progress has been made on the foundational Electronic Patient Record (EPR) infrastructure; by March 2026, 98% of trusts are forecast to have an acceptable EPR. Digital funding will also be allocated via competitive bidding frameworks for enhanced cybersecurity measures. Capital Planning and Investment Priorities The capital guidance supporting the MTPF mandates a stringent approach to investment, intended to ensure alignment with financial sustainability goals. Systems must engage in joint governance to balance system-specific priorities with collective responsibility. Capital proposals are rigorously assessed against several criteria: they must outline expected improvements in clinical or constitutional standards (performance impact); they should ideally finish within 2025/26 (timely completion); and, critically, they must be demonstrably revenue improving or revenue-neutral. This requirement ensures projects manage revenue costs, including capital charges and depreciation, within existing revenue settlements, placing a high bar on transformative capital schemes that require significant sustained operational funding uplift. This capital constraint is particularly acute for the "Hospital to Community" shift. If crucial infrastructure projects for Neighbourhood Health Services, such as community diagnostic or primary care hubs—require an upfront revenue investment for new staffing or higher running costs before acute savings are secured, the "revenue-neutral" rule may inadvertently inhibit the very structural change the MTPF aims to achieve. To mitigate this, £75 million has been specifically allocated in 2025/26 to support localised mental health infrastructure, targeting the reduction of OAPs in acute care, psychiatric intensive care units (PICUs) and rehabilitation placements far from home. Workforce and Leadership Development Workforce efficiency is directly addressed through mandated reforms designed to decouple workforce growth from service delivery growth. The pressure to reduce agency expenditure (minimum 30% reduction) places emphasis on optimising core staffing utilisation. A major reform for productivity is the implementation of new consultant job planning structures. Systems must ensure that 95% of medical job plans are signed off annually in line with business cycles. Furthermore, rigorous system monitoring and assurance of job planned activity must be enacted by the end of 2026/27, with full-year tracking achieved by the end of 2027/28. By 2028/29, this must extend to multi-professional service level activity and job planning. These mechanisms are central to converting clinical time into measurable activity and sustaining the 2% productivity target. The new Management and Leadership Framework, expected in autumn 2025, will further standardize competencies and ethics, providing ICBs and providers with guidance for leadership recruitment and approval. Conclusion and Critical Assessment The NHS England Medium Term Planning Framework (MTPF) 2026/27–2028/29 represents a necessary strategic evolution, shifting the service toward long-term integrated planning built upon the foundational principles of the 10 Year Health Plan. It offers a clear, if narrow, path toward simultaneous performance recovery, aiming for 92% RTT compliance by 2028/29 and structural transformation via the Neighbourhood Health Service models. The primary determinant of the MTPF’s success is the financial feasibility of the transformation. The mandate for all systems to achieve financial balance underpinned by a sustained 2 per cent annual productivity gain creates a highly demanding operational environment. Given historical efficiency rates, achieving this target requires that the investments in digital transformation and the structural shift to community care must immediately yield systemic savings in acute demand and workforce utilisation. If reform benefits are delayed or insufficient, the financial imperative will clash directly with the operational goal of restoring constitutional standards, forcing local leaders into impossible trade-offs. Strategic Recommendations for System Leaders Prioritise Neighbourhood Revenue and Reallocation: Integrated Care Boards must proactively utilize the flexibility afforded by the MTPF to model and enforce the reallocation of revenue resources from high-cost acute capacity into the staffing and development of Neighbourhood Health Service models. This structural funding shift must be executed based on the guidance in the Model Neighbourhood Framework (November 2025) to accelerate demand reduction and validate the MTPF’s financial assumptions. Focus Digital Investment on Productivity: The targeted technology funding (the £400 million stream dedicated to productivity) should be strategically deployed on digital solutions that directly support and measure clinical efficiency gains, particularly those integrated with the consultant job planning reforms.This ensures digital investment translates into quantifiable efficiency improvements needed to meet the 2% mandate. Proactive Financial Resilience and Contingency Planning: Recognizing the historical difficulty of achieving high annual productivity, system leaders must develop robust contingency plans for recurring efficiency savings that exceed the 2% annual target. This requires early identification and management of low-value activity and a rigorous approach to expenditure reduction (e.g., the 30% agency spend target) to absorb inevitable cost pressures and maintain the mandated balanced financial position. Source: https://www.england.nhs.uk/wp-content/uploads/2025/10/medium-term-planning-framework-delivering-change-together-2026-27-to-2028-29.pdf Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

NHS Enablers of Change: Strategic Analysis of Digital, Capital and Workforce Reform Executive Summary: Interlocking Crisis and the Imperative for Integrated Reform The transformation of the National Health Service (NHS) in England is defined by three interconnected "Enablers of Change": Digital Reform, Capital Investment and Workforce Reform. This strategic assessment establishes that the viability of the NHS’s foundational shifts, moving care from hospitals to communities, from analogue to digital, and from treatment to prevention is wholly contingent upon the successful, synergistic execution of these three enablers. The challenge is profound, characterised by a fundamental gap between immediate financial pressure and deeply long-term strategic delivery timelines. The analysis concludes that the primary operational risk facing Integrated Care Boards (ICBs) is the Revenue-Capital Mismatch within Digital Reform. Extensive capital investments in systems like Electronic Patient Records (EPRs) are frequently undermined by a lack of sustained revenue funding necessary for staff training, clinical change management, and long-term maintenance. Furthermore, the primary systemic risk is the Chronological Disconnect between acute public demand for service improvement, reflected in satisfaction levels sinking to an all-time low of 21% in 2024 and the distant realisation of physical infrastructure renewal. Major capital projects, such as those in the New Hospitals Programme (NHP) are scheduled for commencement as late as 2035 to 2039 in regional cases. Therefore, success in the medium term is predicated on ruthlessly leveraging the Digital Enabler to accelerate Workforce productivity gains. This strategy must stabilise immediate operational capacity, deliver the mandated 4% productivity improvement for 2025/26 and effectively mitigate the 10-to-15-year lag in physical capital infrastructure delivery. The failure of any single enabler will result in diminished returns across the entire transformation agenda. The Strategic Landscape: Drivers and Constraints of NHS Transformation The Quadruple Threat: Systemic Challenges Driving Reform The current imperative for fundamental reform stems from a confluence of systemic challenges that threaten the financial and operational sustainability of the health service. Firstly, escalating demographic demand is a critical driver. The number of people aged over 85 is forecast to grow by 55% by 2037, a demographic shift that continues to outstrip comparable countries. This inexorable growth in demand requires not merely incremental efficiency, but fundamental capacity expansion and service redesign across all settings. Secondly, the Workforce Deficit has reached an existential level. Local services report vacancies totalling over 112,000, and inaction is forecast to leave a shortfall of between 260,000 and 360,000 staff by 2036/37. This lack of sufficient staff numbers and appropriate skill mix is explicitly recognised as constraining the capacity of the NHS to transform and already impacting patient experience and productivity. Stabilising and expanding the workforce is, therefore, the essential precondition for the success of digital and capital investments. Independent analysis supports this view, noting that workforce challenges represented a greater threat to health services than funding challenges as early as 2018. Thirdly, the Crisis of Public Trust heightens political pressure. The 2024 British Social Attitudes survey reported that just one in five British adults (21%) were satisfied with the NHS, the lowest level recorded since the survey began in 1983. This political and public volatility forces leadership to prioritise rapid, visible improvements, such as reduced waiting times, potentially at the expense of necessary, slow, and complex deep structural reforms. Finally, the Productivity Mandate for the 2025/26 financial reset imposes an unprecedented constraint. NHS organisations are required to reduce their cost base by at least 1% and achieve a substantial 4% improvement in productivity. This efficiency demand must cover significant mandated cost increases, including final pay settlements, increased employer national insurance contributions, and the accelerated elective waiting list recovery, framing all reform efforts within a critical financial environment. The Three Foundational Shifts Guiding Transformation The reforms are strategically focused on achieving three core structural shifts: Hospitals to Communities: This shift emphasises providing more care outside of traditional acute settings, focusing heavily on developing 'neighbourhood health centres' and increasing investment in general practice and community care capacity.. The aim is to move care "upstream," preventing people from becoming unwell and reducing the reliance on secondary care interventions. Analogue to Digital: The shift targets the major expansion of digital platforms, notably the NHS App, and the strategic adoption of advanced technology, including Artificial Intelligence (AI) and robotic process automation. Treatment to Prevention: This focuses on a proactive approach to health, emphasising prevention, population health management, and addressing the wider determinants of health to minimise the necessity for costly interventions later in the care pathway. Strategic Contradictions and Analytical Preconditions An assessment of the current environment reveals two fundamental strategic contradictions that must be managed. The first concerns the financial feasibility of the Hospitals to Communities shift within the constraint of the 4% productivity target. The British Medical Association (BMA) emphasises that moving care into the community must be managed and funded safely, requiring increased investment in general practice and community care. However, financial analysis indicates that tracing freed-up resources or savings from efficient hospital operations (the source of productivity gains) to community care budgets presents a significant challenge. It is structurally difficult to trace directly from a change implemented in one part of the system to the finance pot or budget line impacted elsewhere]. If hospital productivity gains are realized, but the financial architecture fails to successfully transfer those resources to community services, the community shift stalls due to chronic underfunding. Therefore, integrated digital platforms are required not just for clinical data, but for financial data convergence to prove and validate the economic case for moving care from acute to primary settings. The second critical analytical finding is that financial recovery is dependent on workforce execution. Staffing gaps worsened for years due to poor workforce planning, cuts in training, and high staff attrition. The current financial precariousness is substantially an effect of the chronic workforce crisis, evidenced by the persistent high cost of agency reliance. The ability to meet the challenging 4% productivity target is fundamentally dependent on the success of the Workforce Plan’s retention strategies. Failure to stabilise staff numbers means agency reliance remains high, undermining the possibility of achieving efficiency targets and financial sustainability. Enabler 1: Workforce Reform – The Long Term Plan for Sustainable Staffing The NHS Long Term Workforce Plan (LTPWP), published in June 2023, is positioned as a once-in-a-generation plan aimed at addressing the projected shortfall of up to 360,000 staff by 2037. The plan is supported by the government with over £2.4 billion in additional funding for education and training over five years. Its long-term success is designed to deliver significant financial stabilisation, forecasting agency spend reduction that could cut the taxpayer bill by around £10 billion between 2030/31 and 2036/37. The Three Pillars of the LTPWP The strategy is built on three interdependent pillars: Recruit, Retain, and Reform. Recruit (Education and Expansion): This pillar sets ambitious targets for education expansion. It aims to double medical school training places to 15,000 annually by 2031, with a focus on placing more students in areas with the greatest shortages. General Practice capacity is prioritised with an increase in GP training places by 50% to 6,000 by 2031, a measure vital for realising the shift in care to the community. The plan also commits to almost doubling the number of adult nurse training places by 2031. . Retain (Culture and Flexibility): Given the immediate pressure on staffing, this pillar is crucial, aiming to ensure up to 130,000 fewer staff leave the NHS over the next 15 years. Retention strategies include ensuring staff can work flexibly, providing comprehensive health and wellbeing support, and embedding a commitment to the NHS People Promise. Specific measures include modernising the NHS Pension Scheme to remove disincentives for senior staff, introducing the NHS Emeritus Doctor Scheme to allow recently retired consultant doctors to support outpatient care delivery, and maintaining national funding for Continued Professional Development (CPD) for nurses, midwives and allied health professionals. Reform (Skill Mix and Operating Model): Reform is explicitly defined as improving productivity by working and training in different ways, utilizing broader multidisciplinary teams, and harnessing digital innovation. The plan involves expanding enhanced, advanced, and associate roles to modernise careers, aiming to grow the proportion of staff in these newer roles from approximately 1% to 5% by the end of the 15-year period. There is also a stronger emphasis on developing the generalist and core skills needed to care effectively for patients presenting with multi morbidity, frailty, or complex mental health needs . Connecting Skill Reform to Digital Infrastructure The mandate for a stronger emphasis on generalist skills for multi-morbidity care establishes a dependency on the Digital Enabler. Managing complex patients across acute, community, and mental health settings requires seamless, unified data access. The success of this clinical reform is fundamentally predicated on the functional interoperability of digital systems. If clinical staff lack the ability to easily access a comprehensive, integrated record across different care settings, the administrative burden imposed by fragmented documentation will cripple the efficiency gains expected from the generalist approach. This means workforce training programs, including CPD, must be immediately reformed to integrate practical, real-world instruction on leveraging interoperable digital tools (such as EPRs and CareConnect APIs) to manage cross-system care pathways. Digital enablement is, therefore, not a secondary technology project but an embedded necessity within the core "Reform" objective. Furthermore, a significant gap exists between the long-term nature of recruitment benefits and the immediate need for capacity. Due to the lengthy training pipeline (7 to 10 years for many clinical roles), the massive recruitment targets (doubling doctors and 50% more GPs) are distant strategic benefits. Given the acute public demand for rapid improvement, the Retain pillar (targeting 130,000 staff saved) and the accelerated expansion of quicker-to-train Associate Roles (growing from 1% to 5%) become the only immediate operational levers available to alleviate the short-term crisis and demonstrate progress to the public. Operational failure in retention will critically undermine the entire 15-year workforce structure. NHS Long Term Workforce Plan: Key Targets and Financial Impact LTPWP Pillar Key Target/Metric Timeline Strategic Financial Impact Source Recruit (Education) Double medical school places to 15,000 annually By 2031 Building long-term, stable capacity. Backed by £2.4 Bn training fund. Various Retain 130,000 fewer staff leavers Over 15 years Stabilises existing expertise and mitigates high agency costs. Various Reform (Skill Mix) Grow enhanced/associate roles from ~1% to 5% By end of Plan Drives productivity, frees clinician time, addresses multi-morbidity care needs. Various Financial Savings Goal Reduce agency reliance for projected savings £10 billion between 2030/31 and 2036/37 Underpins the financial viability of the long-term plan. Various Enabler 2: Digital Transformation – Achieving Core Capabilities and Interoperability Digital reform, driven by the Frontline Digitisation Programme (FDP), is intended to be the central mechanism for immediate productivity gains and workforce capacity release. The FDP’s core objective is to support NHS trusts in reaching a minimum level of digital maturity, ensuring core digital capabilities, fast connectivity, and robust cyber-resilience are in place. Frontline Digitisation and EPR Implementation The most visible target for the FDP is the implementation of Electronic Patient Records (EPRs). The national deadline for all trusts in England to have an EPR system implemented to a minimum standard has recently been shifted from March 2025 to March 2026. This transformation is complex, requiring significant investment in time, people, and cost, but is intended to catalyse change in healthcare delivery. The investment context is substantial, with £3.4 billion announced for supporting existing tech and digital capital investment, of which £2.2 billion has been specifically allocated in a recent Budget.. The Crucial Challenge of Interoperability and Standardisation For digital systems to truly enable the Workforce and allow the shift to integrated community care, they must be interoperable. This requires fundamental standardization. NHS England is working towards systems that enable access to patient information through open interfaces, specifically CareConnect APIs. Furthermore, the mandate for clinical terminology requires the implementation of SNOMED CT across primary care (prior to April 2018) and across secondary care, acute care, mental health, and community systems (prior to April 2020). This standardisation is paramount, ensuring that data is not merely shared, but is consistently understood and used across disparate systems and professional domains. The objective of convergence is to ensure staff across multiple organisations within an Integrated Care System (ICS) can access the same patient information. This directly facilitates the ability to document once and share information, which is expected to increase capacity and free up clinical time for patient care. However, inadequate investment in interoperability between systems has been cited as a major concern and a complex challenge associated with digitising the frontline. If genuine, pervasive interoperability is not achieved through rigorous adherence to standards like SNOMED CT, the massive capital investment in EPRs risks becoming siloed, resulting in a significantly reduced return on investment (ROI) and failing to deliver the capacity release necessary to support the over-stretched workforce. Interoperability is thus a critical risk mitigator for the overall transformation cost. Funding Structures and Operational Risks Financial viability remains the greatest barrier to digital transformation. National funding for digital investment is often allocated as capital, creating complex accounting challenges because many modern EPR systems are based on hosted or cloud-based services (Software as a Service, or SaaS). Compounding this, a major barrier cited by local leaders is the critical lack of revenue funding necessary for long-term maintenance, training, and change management. This funding is often described as "short-term and 'drip fed'," impairing the ability of systems to plan and invest over the long term. Furthermore, there are expressed concerns regarding the inequity of funding across different types of providers, particularly disparities between acute, community, and mental health services, which limits the potential for consistent, system-wide digital maturity. The strategic adoption of digital solutions requires a significant shift in operational model. Trust Boards must elevate digital and technology to the same level of importance as finance or quality, viewing it as a core enabler to organisational goals. Crucially, digital organisations must transition away from project-focused IT expenditure to adopting blended funding models (combining revenue and capital) and proactively factoring in life cycle costs. The Contradiction of EPR Deployment and the Productivity Target A significant operational risk is the inevitable short-term reduction in productivity following large-scale EPR implementation. Organisations that have deployed EPRs frequently report substantial productivity dips during and immediately after implementation, often taking longer than anticipated to return to previous productivity levels. Furthermore, forecasts suggest that substantial cash-releasing benefits from EPRs tend to materialise only after ten or more years. The simultaneous mandate to achieve a 4% productivity improvement in 2025/26 creates a direct contradiction if major EPR rollouts proceed without careful management. ICBs must strategically phase EPR deployment, ensuring that immediate productivity targets are met by gains derived from other areas, such as reduced agency spend and streamlined clinical pathways, while openly accounting for the necessary, temporary loss of clinical efficiency during the demanding digital transition period. Digital Reform: Targets, Investment, and Implementation Barriers Digital Programme Area Key Target/Deadline Funding Context Core Implementation Barrier Source Electronic Patient Records (EPR) All trusts implemented to minimum standard March 2026 Initial reduction in productivity; long-term ROI (10+ years). Various Capital Investment (Existing Tech) Allocated funding for tech and digital capital £3.4 billion total, £2.2 billion recently allocated Funding often short-term, 'drip fed,' and lacks sufficient revenue support. Various Interoperability Standard Use of SNOMED CT as clinical terminology Mandated across acute/community/mental health (pre-April 2020) Lack of investment and expertise in integrating disparate systems. Various Digital Leadership Digital viewed at Board level as a core enabler Ongoing Need to shift from IT-driven project funding to blended funding models. Various Enabler 3: Capital Investment – Modernising Infrastructure and Estate Capital investment addresses the poorest quality estates and ensures a safe, sustainable environment for healthcare delivery, specifically mitigating critical infrastructure and safety risks.. Strategic Capital Allocation NHS capital spending is divided across several critical streams. Nationally allocated funds, totaling £1.9 billion, cover strategic projects such as new hospitals and hospital upgrades (Sustainability and Transformation Plan schemes). A further £2.0 billion covers other national capital programme investments, including funds for elective recovery, diagnostics, technology (Digital Enabler), and mental health dormitory eradication. To support local planning, systems have been provided with indicative allocations and greater certainty regarding core operational capital. Systems are encouraged to assume they will receive at least 80% of their 2025/26 core allocation in subsequent years of this Parliament, a mechanism designed to accelerate local investment decisions. Crucially, leaders are also encouraged to develop capital schemes that draw on multiple funding streams to deliver multiple objectives, reinforcing the necessity of integrated planning. The New Hospitals Programme (NHP) and Chronological Disconnect The New Hospitals Programme (NHP) is the cornerstone of long-term estate modernization. The NHP aims to deliver significant efficiencies through a standardised design approach, known as 'Hospital 2.0,' which leverages economies of scale, standardises designs, and improves productivity to maximise modern technologies. The program maintains a focus on safety, prioritising schemes constructed using Reinforced Autoclaved Aerated Concrete (RAAC) due to substantive safety risks. Long-term funding for the NHP, once it reaches a "steady state" post-2030s, is estimated at an overall envelope of £15 Billion per five-year window, averaging £3 Billion annually. However, the NHP’s wave-based delivery model exposes a significant Chronological Disconnect. The Workforce Plan (LTPWP) is designed to generate sustainable capacity now and over the next 15 years, but the physical infrastructure required to optimise this new workforce is often delayed. For instance, major regional capital schemes in the North West, such as the Royal Lancaster Infirmary and Royal Preston Hospital, are scheduled to commence construction in Wave 3, placing their start dates between 2035 and 2039. New Hospitals Programme (NHP) Wave 3 Example Timelines and Investment NHP Scheme (North West Examples) Wave of Delivery Expected Construction Start Window Estimated Cost Envelope Source Royal Lancaster Infirmary Wave 3 2035 to 2038 £1 billion to £1.5 billion Various Royal Preston Hospital Wave 3 2037 to 2039 £2 billion or more Various NHP Steady State Annual Average N/A Post-2030s £3 billion annually (£15bn per 5-year wave) Various The Forced Substitution of Digital for Capital The long time lag in physical Capital delivery (up to 15 years for Wave 3 schemes) means that the NHS must find ways to deliver 2030s care standards within estate constraints that may date back to the 1970s. This critically elevates the role of the Digital Enabler. Digital solutions, such as remote monitoring, AI-enabled diagnostics, and virtual wards (funded via the £2.0 billion national technology programmes), become non-negotiable substitutes for immediate physical capacity expansion. Capital investment in technology must temporarily replace Capital investment in estate in the short to medium term to address patient demand and provide capacity relief. A further risk is that the standardisation inherent in the NHP's Hospital 2.0 design, while intended to improve speed and value, must accommodate rapid technological evolution. If the design templates prove too rigid, they risk locking systems into estates that become technologically obsolete by the time they open post-2040. Capital planning must therefore incorporate extreme flexibility and modularity, informed directly by the rapid evolution predicted within the Digital Enabler, particularly concerning clinical workflows and AI integration. Finally, the NHS’s commitment to becoming the world's first net zero health system places an additional capital and operational pressure on infrastructure. If the NHP (Wave 3) is delayed, the existing, less energy-efficient estate continues to contribute significantly to national emissions (estimated at 4% to 5% of the UK total), creating a long-term environmental and operational cost burden that must be factored into financial planning alongside core clinical needs. Strategic Interdependence and The Productivity Mandate The success of the 4% productivity target for 2025/26 relies entirely on the successful integration of the Digital and Workforce reforms, offsetting the lack of immediate physical infrastructure benefit. Digital as the Catalyst for Workforce Productivity Workforce reform explicitly relies on harnessing digital and technological innovations, such as speech recognition, robotic process automation, remote monitoring, and AI, to free up clinicians' time and increase flexibility in deployment. The aim is to allow staff to spend more time with patients. Digital solutions, including virtual wards and digital care plans, are essential operational tools that support the development and implementation of new, flexible ways of working. Furthermore, integrated digital systems are fundamental for managing the increasingly complex cohort of patients with multi morbidity, frailty, or mental health needs, a core focus of the reformed workforce skill mix. Achieving the 4% Productivity Target The requirement to achieve 4% productivity improvement in 2025/26 is challenging, though recent figures indicate acute trusts increased productivity by 2.7% between April 2024 and March 2025, achieved through measures such as reduced agency reliance, faster same-day discharges, and better use of technology]. However, simply identifying efficiency gaps (eg. length of stay variation, high bank/agency use) through national "productivity and efficiency packs" is only the first step. The critical operational challenge lies in converting these identified opportunities into sustained, recurrent savings that are successfully embedded into the cost base year after year. Operational success requires disciplined governance, focused prioritisation of a limited number of high-impact initiatives, and developing delivery capability that remains within the organisation, often formalised through a Management Operating System (MOS). The observed 2.7% productivity increase, while positive, must be viewed analytically as internal efficiency improvement. It does not address the fundamental capacity deficit resulting from the long-term workforce shortage. Until the Workforce Plan delivers massive recruitment, efficiency gains may simply be consumed by perpetually increasing patient demand. Therefore, the immediate 4% target for 2025/26 functions as a critical test of the interdependence of the Digital (flow, data utilisation) and Workforce (reduced agency, skill mix) enablers, as they must deliver immediate cash savings independently of the distant Capital benefits. Interdependence as a Financial and Planning Necessity Given the constrained nature of all three funding envelopes, short-term digital capital, expensive workforce training, and constrained physical capital, ICB leaders are explicitly encouraged to develop schemes that utilise multiple funding streams to deliver multiple objectives. This makes integrated business casesmandatory. For example, a successful business case for procuring an EPR system (Capital) must demonstrate a robust return by linking the expenditure to guaranteed workforce retention rates (Workforce), projected agency savings, and resulting efficiency gains (Productivity). Policy integration has ceased to be merely an abstract objective; it is now an explicit mechanism for accessing and justifying scarce financial resources. Feasibility, Financial Risks, and Systemic Challenges External Scrutiny and Feasibility Check Independent assessments from organizations like the Nuffield Trust and The King’s Fund highlight the delicacy of the current situation. They warn that the government must walk a fine line between meeting public demands for rapid improvements and avoiding the temptation of "throwing more money... at a system in need of deeper reform". External analysis consistently confirms that the chronic workforce crisis presents the overriding challenge to the NHS, with the failure to stabilise staffing fundamentally undermining all attempts at financial and quality improvement. The government's 10 Year Health Plan acknowledges the dramatic need for change with the rhetoric that the NHS must "reform or die," making the credible delivery of the three foundational shifts a test of political viability. Financial Risks and Governance Gaps The 2025/26 financial reset requires systems to operate within constrained budgets while meeting the demanding 4% productivity improvement and 1% cost reduction. A critical ongoing financial challenge that inhibits the strategic shift to community care is the difficulty in tracing the value. It remains hard to prove that financial gains generated by increased efficiency in one area (eg secondary care) directly translate into recurrent funding for preventative services or general practice. This difficulty hampers the pragmatic movement of financial resources toward the community-based care model. Analysts suggest that overcoming this requires operating with "a degree of pragmatism over perfectionism" and reforming financial governance cadence. The current reporting cycles often prioritize adherence to historical, granular budget lines, which can work against the future-focused, integrated accounting needed to validate system-wide transformation. Achieving the shifts requires reforming governance to prioritise integrated system value and the long-term recurrence of savings over short-term, siloed budget adherence. Systemic Implementation Gaps At the local level, significant effort is being invested in strategic alignment, as seen in the Lancashire and South Cumbria ICB’s production of a Digital and Data Strategy 2024–2029 and a Five-Year Workforce Strategy]. These documents adhere to national frameworks and aim for integrated system delivery, supporting the quintuple aim of healthcare (patient experience, outcomes, accessibility, resource use, and workforce experience). However, public-facing materials often lack the specific, quantifiable objectives or early outcomes related to recruitment, retention, and detailed capital integration. This lack of granular transparency can hinder local accountability and limit the alignment of stakeholders across the complex ICS environment. Furthermore, a significant systemic challenge is cultural inertia. Historically, organisations and professionals within the system have operated in silos. Changing this entrenched culture, a prerequisite for integrated workforce thinking and seamless digital adoption is a long-term behavioural change project that runs directly counter to the immediate pace and quantitative metrics required by short-term financial and productivity mandates. Strategic Recommendations for Integrated System Delivery Based on the strategic analysis of the three enablers and their critical interdependencies, the following high-level recommendations are provided for ICB Senior Executives and DHSC Policy Advisors: Mandate Blended Funding Models for Digital Capital: ICBs must move immediately beyond the capital/revenue dichotomy by developing and enforcing blended funding models for digital schemes. Revenue streams must be ring-fenced specifically for training, clinical change management, and long-term maintenance of EPR systems. This mitigates the critical short-term productivity dip and ensures that the massive capital investment provides a maximised return on investment, delivering sustained benefits rather than siloed, short-lived IT assets. Elevate Retention and Reform as Immediate Capacity Levers: Acknowledge the long time lag inherent in major recruitment (Recruit pillar) and physical construction (Capital NHP Wave 3). ICB leadership must intensify focus on the Workforce "Retain" and "Reform" pillars (flexible working, modernised careers, associate roles) as the primary mechanism for generating rapid, observable capacity gains. These are the only immediate tools available to address acute public demand and deliver against the 4% productivity target in the near term. Prioritise Interoperability as Financial Control: Treat investment in genuine, mandatory interoperability standards (e.g., SNOMED CT implementation and CareConnect APIs) not merely as a clinical or technical objective, but as a critical financial control mechanism. This interoperability is required to generate the transparent, auditable financial data necessary to trace cost savings (from hospital efficiency) to new funding allocations (for community services), thereby validating the economic case for the fundamental shift of care from acute settings to the community. Adopt Long-Term Risk Mitigation through Digital Substitution: Formally incorporate the fact that the Digital Enabler must temporarily substitute for unavailable physical Capital due to the extended NHP timelines. ICBs should strategically prioritise significant capital investment in remote monitoring, virtual wards, and AI-enabled diagnostics (via national technology programme funds) to deliver measurable capacity and system resilience, mitigating operational strain on the existing, aging, and potentially compromised estates. Simplify and Prioritise Productivity Initiatives through Governance Reform: To ensure the 4% productivity target converts to sustained, recurrent savings, ICB governance must adopt a disciplined Management Operating System (MOS). This involves shifting the emphasis of financial reporting away from historical budget adherence and toward prioritising a limited portfolio of high-impact initiatives that focus on embedding efficiency gains into the cost base, thereby preventing the dilution of leadership focus and ensuring measurable progress year after year. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors MedTech and HealthTech events: Q4 2025 Nelson Advisors will be speaking, presenting and chairing a number of panels at MedTech and HealthTech conferences and events in October, November and December 2025. Please feel free to come and meet us in person or to book a meeting with us online please visit https://scheduler.zoom.us/nelson-advisors/meeting October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel https://healthcare-summit.co.uk Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel https://healthcare-summit.co.uk NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland – Attending the NHS Innovation Accelerator sessions https://nhscepcommunity.com/events/179287 Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel https://www.globalhealthsaudi.com/en/home.html November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel https://impactx2050.com/healthtechx MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel https://med-tech.world/malta MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards https://med-tech.world/malta Leaders in Health Summit 2025 https://wellfounded.health/leadersinhealth# December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack: Emerging Vulnerabilities in Healthcare”Panel https://healthtechforward.com HealthInvestor Power List Awards 2025, London, UK – Judging Panel https://healthinvestorpowerlist.com Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading Consumer HealthTech M&A Advisors in Europe? Executive Overview and Strategic Summary Introduction: The Strategic Significance of European Consumer HealthTech The European Consumer HealthTech (CHTx) sector, which sits at the critical nexus of traditional Over-the-Counter (OTC) consumer goods and advanced Digital Health solutions powered by Artificial Intelligence (AI), has achieved accelerated strategic significance. This growth is fundamentally driven by shifting global demographics, particularly the expansion of the over-50 population, and a concurrent rise in consumer demand for proactive, self-directed wellness solutions. As public healthcare systems across Europe strain under demographic and cost pressures, consumers are increasingly turning toward CHTx companies for accessible, margin-attractive, and stable self-care solutions. The CHTx market remains fundamentally fragmented on a global basis; data indicates that the top three players in major consumer health categories collectively hold only 27% market share. This inherent fragmentation provides sustained opportunity for scale-oriented Mergers & Acquisitions (M&A) activity. Given the complex regulatory requirements and long product development cycles inherent to healthcare, M&A is often the most popular and expedient entry point for companies seeking rapid scale in this market.Consequently, the requirement for expert advisory services, capable of navigating regulatory constraints while translating scientific credentials into compelling consumer positioning, is paramount. Analysis of the 2025 market environment reveals a phase of cautious yet discernible rebound in European Healthcare M&A. This resurgence is characterised by a fundamental strategic divergence: while deal volume remains subdued compared to historical peaks, a significant spike in aggregate deal value confirms the return of large, "high-conviction" transactions. This shift signals strategic selectivity among acquirers and investors. M&A advisory is moving away from broad, lower-conviction mandates prevalent in the preceding two years toward complex, high-stakes transactions, such as massive corporate carve-outs or the creation of pan-European investment platforms. This environment fundamentally benefits two distinct classes of advisors: those who can structure deals requiring vast pools of capital and those who possess the deep specialisation required to accurately vet and prove asset quality and technological compliance in niche segments. The Dual Advisory Model Thesis A comprehensive analysis of the European CHTx M&A landscape reveals that a singular definition of a "leading" advisor is insufficient. Instead, leadership is stratified into a Dual Advisory Model, where the selection of the optimal advisory firm depends entirely on the client’s strategic objective: maximum scale and capital access, or deep domain specialisation. Category I: Global Scale Leaders (The Titans) These institutions are dominant in terms of aggregated deal value and offer unmatched access to global debt and equity capital markets. Firms in this category, such as Goldman Sachs and Rothschild & Co, are essential for executing mega-deals, providing the necessary liquidity, structuring, and multi-jurisdictional capacity required for large corporate divestitures and high-profile platform acquisitions. Their primary function is enabling liquidity and providing unparalleled strategic access. Category II: Specialised Domain Experts (The Boutiques) This category comprises firms dedicated exclusively to the healthcare technology ecosystem. They are crucial for technical due diligence, operational credibility and deep expertise in critical market niches, such as Healthcare AI, Digital Health, and specific Consumer HealthTech sub-sectors. Firms like Nelson Advisors and Artis Partners are valued not primarily for their balance sheet access but for their nuanced understanding of scaling CHTx assets, navigating complex technological valuation metrics, and assuring regulatory readiness. Volume-Value Divergence as a Strategic Indicator The divergence observed between deal volume and deal value in the 2025 market underscores the strategic imperative of selectivity. The significant spike in deal value confirms that, despite overall market caution, large, high-quality, "high-conviction" transactions are returning. This strategic selectivity means that advisors are no longer merely facilitating broad sales processes; they are acting as essential strategic partners in market entry and expansion. For acquirers, the requirement to prove the quality of the asset, particularly its capacity for AI-driven transformation and adherence to forthcoming European digital health regulations is paramount. This market dynamic elevates the specialised capabilities of domain experts who can perform precise technological due diligence alongside the structuring prowess of the global investment banks. Market Context: Drivers, Capital Flow, and Valuation Benchmarking (2024–2026) The Centrality of Private Equity and Roll-Up Strategies Private Equity (PE) firms currently stand as the predominant drivers of recent European HealthTech M&A activity, with sponsor buyout deals spiking by an extraordinary 276% year-to-date in June 2025 compared to the same period in 2024. This surge is not random deal flow but rather a systematic execution of two key strategies. First, PE firms possess substantial "dry powder" and are highly motivated to deploy capital in high-quality assets following a period of macroeconomic pressure. Second, PE firms are aggressively pursuing "roll-up" strategies, where they acquire established tech start-ups to serve as platforms for acquiring numerous smaller rivals. This strategy is designed to build dominant conglomerates and generate liquidity from portfolios in an environment where traditional Initial Public Offerings (IPOs) remain a limited option. A defining characteristic of these roll-up strategies in CHTx is the infusion of technology, particularly AI, into acquired businesses to drive efficiency, margin improvements, and competitive differentiation. This means the advisor's role is now tied to their ability to assess not just the current financials of a target but also its technological stack and capacity for AI-driven transformation post-acquisition. This generates consistent demand for mid-market M&A advisors who are capable of identifying, vetting, and executing complex bolt-on acquisitions efficiently and frequently. Inbound Cross-Border Capital and Geopolitical Influences Europe has cemented its position as an increasingly attractive destination for global investors, particularly those originating from the US and Asia. Geopolitical tensions and the complex US–China relationship, alongside a perpetual focus on acquiring world-class technology, have made Europe an appealing alternative for investment. The trend of US sponsors seeking European platforms is evidenced by several notable recent transactions. These include KKR’s acquisition of Karo Healthcare from EQT6, a major transaction aimed at creating a pan-European consumer health powerhouse. Another instance is Avista’s acquisition of Terrats from Miura, intended to support international expansion and other growth initiatives. This sustained influx of cross-border capital requires advisory firms to maintain robust international teams and sophisticated cross-border M&A execution capabilities. Firms positioned globally, such as DC Advisory, Nelson Advisors and the Global Banks, are best suited to capture this inbound M&A flow. Valuation Benchmarking and the AI Premium The current M&A environment is characterised by a "flight to quality," where discernible profitability and technological alignment determine premium valuations. Advisors must possess the analytical rigour to structure and defend valuations based on technology multiples (akin to SaaS/AI metrics) rather than just traditional consumer health metrics. For CHTx companies demonstrating positive earnings, Enterprise Value (EV) to EBITDA multiples are generally observed between 10x and 14x as of June 2025, representing a slight increase from the 10x to 12.5x range seen in 2024. However, the high-growth segments of CHTx, especially those driven by technological convergence, command a significant premium. Highly innovative segments, notably AI-driven solutions, telehealth platforms, and advanced analytics, are commanding higher revenue multiples, often reaching 5.5x to 7x revenue or more. This premium reflects the perceived strategic value of scalable technology that aligns with the transition toward value-based care and demonstrates measurable cost savings or improved patient outcomes. This market structure confirms that success for leading advisors is now contingent upon their ability to quantify the long-term value of digital intellectual property. Category I: The Global Investment Banking Titans (Scale and Strategic Structuring) The leading global investment banks define the top tier of the European CHTx M&A market by providing the essential foundation of capital coordination, liquidity, and large-scale transaction structuring. Goldman Sachs (GS): The Leader by Value and Strategic Transformation Goldman Sachs consistently ranks as the paramount advisor in Europe by aggregated deal value. In 2024, GS secured the #1 M&A financial advisor ranking in Europe by value, with a reported deal value of $97.5 billion.This value leadership continued into the first half (H1) of 2025, where GS topped the rankings by deal value, facilitating $23.8 Billion in transactions. In the CHTx context, GS’s core mandate is serving as the leading advisor on capability-enhancing and large-scale technology convergence deals. They provide unparalleled access to global capital markets, a necessity for financing major platform acquisitions, debt restructuring, and securing large capital commitments. The firm's indispensable structural role in the CHTx market is most recently highlighted by its mandate on the Sanofi consumer health division carve-out. GS was one of four global institutions, alongside Bank of America Merrill Lynch, BNP Paribas, and Morgan Stanley, mandated to manage the separation of the consumer health division, which could be valued at approximately $20 billion. This mandate confirms that corporate divestitures of this size are the primary source of mega-deal supply in CHTx. By structuring these multi-billion-euro transactions, GS and its peers are functionally creating the large-scale investment platforms (e.g., KKR/Karo) that PE firms and strategic buyers ultimately target, elevating their role beyond mere transaction execution to that of structural market enablers. The firm's commitment to maintaining sector leadership is reinforced by institutional appointments, such as Philippe Gallone joining as Partner and Head of Healthcare Investment Banking in EMEA. Rothschild & Co (R&Co): European Volume and Mid-Market Execution Rothschild & Co (R&Co) maintains its stature as a leading financial advisor in Europe, consistently topping league tables by volume. In 2024, R&Co was ranked #1 by deal volume, completing 132 transactions, demonstrating the deepest and most consistent European market coverage. The firm has maintained its #1 ranking in Europe by number of completed deals for over 15 years. This volume leadership is strategically crucial for the CHTx sector, as it signifies R&Co’s consistent strength in mid-market transactions, which are essential for identifying and aggregating niche AI and HealthTech assets. Given the high volume of "roll-up" strategies being pursued by Private Equity firms in 2025, R&Co's volume leadership aligns perfectly with the strategic imperative to execute multiple, smaller bolt-on transactions rapidly. Their extensive operational presence across 42 countries further facilitates complex cross-border execution, a critical factor since CHTx strategies often rely on navigating localised regulatory and brand dynamics. Other Global Players and Parallel Advisory Services Several other global firms play essential roles in the European CHTx advisory ecosystem: PwC and Deloitte: While these firms are typically recognised for their extensive accounting and consulting capabilities, they are major players in the M&A space. PwC led deal volume in the first half of 2025 and crucially advised on the financial due diligence for KKR’s pan-European platform acquisition of Karo Healthcare. Deloitte is also noted among the top mid-market M&A and strategy advisors for MedTech and life sciences in Europe. Morgan Stanley and Bank of America Merrill Lynch: Their inclusion in the Sanofi carve-out mandate underscores their capacity for handling ultra-large, strategic corporate separations. Houlihan Lokey (HL): HL is recognised for its dedicated healthcare teams, focusing on capital-raising and M&A expertise for European medical technology clients. The firm maintains a strong sector presence through leadership such as Paul Tomasic, Managing Director and Head of European Healthcare. Their capabilities span healthcare technology and financial restructuring, which is highly relevant in the current volatile financing market. The dominance of the Global Scale Leaders is summarised in the following metrics from the 2024 market data: European HealthTech/Healthcare M&A Financial Advisor Rankings (2024 Metrics) Advisory Firm Primary Metric Achieved (2024) Reported Deal Value (2024) Core M&A Strategy Relevance Goldman Sachs (GS) #1 by Value $97.5bn Strategic transformation, global capital access, large-scale convergence deals. Rothschild & Co #1 by Volume (132 deals) N/A (Ranked #9 by Value) Deepest European coverage, consistent mid-market transactions, identifying niche AI assets. PwC Leading by Deal Volume (H1 2025) N/A (Led by GS in value H1 2025) Active mid-market advisory and essential financial due diligence support. Category II: The Specialist Consumer HealthTech Boutiques (Niche Expertise) While the global banks command value and volume, the specialised advisory firms are indispensable for providing the technical and operational depth necessary to de-risk and accurately value complex digital and technology-intensive CHTx mandates. Nelson Advisors: Exclusive Focus on Consumer HealthTech and AI Nelson Advisors stands out due to its status as a highly specialised M&A advisory firm exclusively dedicated to the European healthcare technology (HealthTech) sector, with explicit specialisation in Consumer HealthTech, Digital Health, Health IT and Healthcare AI. Unique Value Proposition and Credibility The firm employs a distinct "Founders for Founders" approach, leveraging the direct entrepreneurial experience of its leadership, who have successfully built, scaled, and exited four HealthTech businesses since 2012, including one specifically in the Consumer Healthcare market. This provides a unique competitive edge in the CHTx M&A landscape. This entrepreneurial credibility provides a profound understanding of the operational complexities inherent in scaling CHTx assets, offering an operational due diligence lens that generalist banks typically lack. For strategic acquirers and PE funds, this expertise acts as a powerful signal that the target asset has been stress-tested for real-world scaling and exit potential, often commanding a valuation premium. Nelson Advisors’ strategy is acutely aligned with the 2025 market rebound, specifically positioning them to guide clients through complex transactions that capitalise on high-growth AI areas. They are consistently identified in the market as necessary specialists for navigating niche AI/HealthTech mandates. DC Advisory: Mid-Market European Healthcare and Relationship Model DC Advisory distinguishes itself through its championing of the "return of the relationship-driven advisory model" in Europe, emphasising personalised service and senior banker involvement throughout the deal process. This personal approach is highly valued by clients in the complex, post-2023 selective market environment, where proprietary deal flow often supersedes mass auctions. The firm also possesses significant international reach, with teams spanning Europe, Asia, and the US, providing a unique vantage point across global markets. This structure positions DC Advisory well to capitalise on the increasing cross-border interest from US and Asian investors seeking European platform assets. While DC Advisory’s direct consumer health mandates are not fully detailed in the recent analysis, the firm actively analyses and highlights major consumer health deals, such as KKR’s acquisition of Karo Healthcare, indicating their deep involvement in the broader European platform M&A space. Artis Partners and DeepTech/AI Mandates As technology becomes the primary determinant of valuation in CHTx, specialised firms focusing purely on advanced technology become essential. Artis Partners is noted for its focused mandates in AI and DeepTech. These specialised firms are crucial for companies operating at the cutting edge of algorithmic development and clinical data application, offering the necessary technical expertise to structure and value proprietary, high-tech assets accurately. The specialised focus areas of the leading boutique advisors are outlined below: Specialised Advisory Focus Areas in European Consumer HealthTech M&A Advisory Firm Core Specialisation Primary Geographic Focus Unique Value Proposition Nelson Advisors Consumer HealthTech, Digital Health, Healthcare AI UK, Europe, North America Entrepreneurial expertise ("Founders for Founders"), specialised sector depth, and market intelligence publications. Artis Partners AI, DeepTech, B2B SaaS Europe and US Focused mandates on advanced technology and scientific credentials critical for high-tech assets. DC Advisory European Healthcare (Mid-Market) Europe, Asia, US Unique cross-border vantage point; relationship-driven advisory model for platform deals. Transaction Analysis and Advisory Mandates Recent large-scale transactions illustrate the distinct roles played by the different advisory tiers in defining the current CHTx market structure. Case Study 1: Large-Scale Platform Creation (KKR/Karo Healthcare) KKR’s acquisition of Karo Healthcare from EQT6 to establish a pan-European consumer health powerhouse exemplifies the platform strategy pursued by US financial sponsors in Europe. This transaction involved substantial capital coordination and extensive due diligence to ensure the acquired asset was truly "platform-ready". The advisory details show a collaborative model: while International Plc acted as the financial advisor to Karo, PwC played the critical role of advising on financial due diligence. This case study confirms that major platform deals require not only substantial financial structuring (likely involving a global investment bank for capital) but also detailed operational and accounting support from large consulting firms (PwC) to manage the integration complexity. Case Study 2: Corporate Divestitures (Sanofi Consumer Health Carve-out) The pending separation of Sanofi’s consumer health unit, which pulled down €5.18 Billion ($5.6 Billion) in net sales during 2023 and is valued at potentially $20 billion, represents a massive, market-making event. This deal will generate one of Europe's largest independent CHTx assets, attracting interest from major PE groups like Advent International, Blackstone, Bain Capital, CVC Capital Partners, EQT AB, and KKR & Co. The sheer scale and complexity of separating a global division from a pharmaceutical giant necessitate the involvement of the absolute elite global banks. The advisory mandates for this carve-out were given to Bank of America Merrill Lynch, BNP Paribas, Goldman Sachs, and Morgan Stanley. This concentration of mandates among the top-tier institutions confirms that they possess the institutional depth, complexity management expertise, and essential capital markets reach necessary to structure and execute multi-jurisdictional corporate separations of this magnitude. This cements their irreplaceable role as leaders in CHTx supply generation. Regulatory Headwinds, Technology Tailwinds, and Future Outlook The leading CHTx advisor must demonstrate explicit foresight regarding European regulatory mandates, as these statutes are transitioning from being mere legal concerns to acting as primary drivers of due diligence and valuation. The Regulatory Imperative (2024–2025 Timeline) The immediate proximity of major European regulatory milestones creates a strategic urgency in M&A planning, demanding rigorous technical and legal scrutiny from advisors. EU AI Act (August 2024): This landmark legislation, soon to take effect across the EU, will impose critical compliance burdens on CHTx solutions leveraging Artificial Intelligence. Advisors must perform deep technical diligence to assess liability and compliance risks associated with proprietary AI models used in consumer-facing health applications. Failure to demonstrate robust compliance will incur a significant regulatory discount, while platforms showcasing compliant, future-proof AI infrastructure will command a premium. European Health Data Space (EHDS) (March 2025): The EHDS is designed to harmonise health data exchange and interoperability across EU member states. For CHTx assets, especially Digital Health platforms, readiness for EHDS integration will be perceived as a major factor for scalability and valuation. Advisors who can confirm that a target’s data architecture is EHDS-ready will secure a valuation premium, as the acquirer can leverage seamless cross-border data utilisation and potential monetisation. This tight regulatory timeline is creating a strategic bifurcation: Acquirers must either accelerate proprietary deal flow to close transactions before the full complexity of compliance is mandated, or they must exclusively target highly compliant, de-risked assets. The value of specialist advisors who can quantify the financial impact of both regulatory discounts and premiums is therefore significantly amplified. Technology Tailwinds: AI as Critical Infrastructure The maturation of AI solutions is fundamentally transforming them from experimental tools into "critical, scalable infrastructure" for healthcare delivery. This transformation drives continued acquisition appetite, particularly from firms (both strategic and financial) seeking to embed robust AI capabilities into their core offerings. This strategic imperative ensures that high-value mandates will flow to advisory firms focusing on this technological convergence, such as Nelson Advisors, Artis Partners and the specialist technology teams within global houses. The following table summarises the key regulatory and market catalysts driving advisory demand: Key Regulatory and Market Catalysts Influencing European HealthTech M&A (2024-2026) Catalyst/Milestone Date/Period Impact on Consumer HealthTech M&A Valuation Implication EU AI Act August 2024 (Implementation) Imposes compliance imperatives, demanding rigorous technical due diligence for AI-driven CHTx products. Premium for compliant, robust AI infrastructure; discount for non-compliant or high-risk systems. European Health Data Space (EHDS) March 2025 (Expected) Drives data interoperability across member states, increasing value of platforms with scalable data capabilities. Increased valuation for platforms enabling seamless cross-border data utilisation and monetisation. Private Equity "Roll-Up" Surge YTD 2025 (276% increase) Fuels consolidation and intense competition for high-quality assets, necessitating high-speed M&A execution. Sustained high EV/EBITDA multiples (10-14x) for profitable, platform-ready assets. Strategic Recommendations and Conclusion Framework for Advisor Selection (Client Profile Matrix) The determination of the "leading" advisor in European CHTx M&A is dependent upon the specific strategic objective of the client. The optimal advisor must align with the asset's size, technological maturity, and required capital structure. The current market environment, characterised by high financing costs and regulatory complexity, has caused clients to seek a relationship-driven advisory model, displacing generic mass auctions. Acquirers increasingly rely on trusted, senior bankers to identify proprietary, de-risked deal flow. The strategic choice of an advisory partner should adhere to the following framework: Strategic Advisory Recommendations Based on Acquirer Profile Client Profile Strategic Objective Primary Advisor Mandate Necessary Co-Advisors Rationale Global Acquirer (>$5bn cap) Corporate carve-out, IPO, large-scale platform acquisition (e.g., Sanofi, KKR/Karo). Goldman Sachs, Morgan Stanley(Scale & Capital Access). PwC/Deloitte (Due Diligence), Specialised Legal Counsel (Regulatory). Leverage capital markets access and deep expertise in structuring complex, multi-jurisdictional financial engineering. Private Equity Fund Mid-market "roll-up" strategy, platform expansion, rapid technology integration. Rothschild & Co(Volume & European Depth) & Nelson Advisors(Specialisation). Artis Partners (AI Vetting). Combines R&Co's volume and regional coverage with specialist depth for CHTx technology and operational due diligence. Specialised Founder/CEO Exit of a high-growth Digital Health or Consumer HealthTech asset (typically $50M - $500M EV). Nelson Advisors(Consumer HealthTech Specialisation) DC Advisory, Houlihan Lokey (Mid-market placement). Utilises deep domain expertise and "Founders for Founders" credibility to defend premium tech valuations and target specific, strategic buyers. Conclusion The leading Consumer HealthTech M&A advisors in Europe operate effectively within the prescribed Dual Advisory Model, demonstrating competence in either global liquidity provision or deep technological specialisation. The Global Scale Leaders, anchored by Goldman Sachs (leading by value and structuring complex carve-outs like Sanofi's) and Rothschild & Co (leading by volume and mid-market execution for roll-up strategies) are essential for generating the fundamental supply and liquidity required for high-value transactions. The Specialised Domain Experts, led by Nelson Advisors, with its exclusive focus on Consumer HealthTech, AI and its "Founders for Founders" operational credibility, provide the critical technical and operational diligence necessary. In a regulatory climate defined by the EU AI Act and EHDS, these specialised firms are vital for de-risking assets, accurately valuing complex technology stacks, and ensuring that strategic investment targets are compliant, scalable, and capable of generating a premium valuation. Ultimately, the optimal advisory solution for CHTx in Europe requires a symbiotic relationship between these two categories, ensuring global capital meets verified, high-quality, and compliant local innovation. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Menlo Ventures' inaugural 2025: The State of AI in Healthcare Report The AI Inflection Point: Strategic Review of Menlo Ventures' 2025 State of AI in Healthcare Executive Summary: The End of the Laggard Era Strategic Overview: The Flipped Script The inaugural 2025: The State of AI in Healthcare Report from Menlo Ventures marks a critical inflection point, confirming that the healthcare industry has decisively moved past its entrenched reputation as a digital laggard. The analysis demonstrates a profound reversal, positioning the $4.9 Trillion industry as a leader in enterprise AI adoption. This accelerated commitment is quantified by key adoption metrics: the sector is now deploying AI at 2.2 times the rate of the broader economy. This transformation is not theoretical; it is validated by a massive infusion of capital directed at operational deployment. Total AI spending in healthcare surged to $1.4 Billion in 2025, representing nearly a three-fold increase from the previous year’s total. Crucially, the vast majority of this capital is allocated to production deployments, signalling the decisive end of the proof-of-concept and piloting phase for market leaders. Organisations are prioritising trusted, production-ready solutions, willing to pay a premium for systems that mitigate the significant risks associated with failure, including operational disruption, patient harm, and reputational damage. The investment strategy is overwhelmingly focused on financial and operational triage. Providers dominate the expenditure, accounting for $1 Billion, or 75% of the total spend.This capital is concentrated in areas promising immediate, measurable ROI, primarily ambient clinical documentation (representing $600 Million) and back-office Revenue Cycle Management (RCM) automation ($450 million). These investments directly target the industry’s most pressing operational crises: pervasive physician burnout, critical labor shortages, and administrative overhead that severely compresses margins. Identified Market Dynamics and Strategic Imperatives The rapid acceleration observed in the provider segment is not uniform across the entire healthcare ecosystem. The marketplace is undergoing significant strategic bifurcation. While health providers (systems and outpatient facilities) have aggressively shortened their procurement timelines (by 18% to 22%), payers have seen their buying cycles lengthen by 20%.This divergence reflects fundamentally different postures toward AI, with providers treating adoption as a necessity driven by immediate operational distress, while payers remain more cautious and deliberative, focused on risk mitigation and internal experimentation. The dramatic increase in adoption velocity, evidenced by the 7x increase in deployed solutions over 2024, suggests a fundamental shift in the strategic mandate for large health systems. AI is no longer categorized as an optional efficiency tool but has become a mandatory, defensive operational strategy. The acute post-pandemic environment, characterized by rising labor costs and administrative complexity, has amplified the cost of inaction beyond the cost of adoption. This structural urgency explains why a leading institution like Kaiser Permanente executed the largest generative AI rollout in healthcare history, Abridge's ambient documentation solution, faster than any technology implementation in the organisation’s preceding 20 years. The AI Imperative: Scale, Velocity, and Institutional Commitment Quantifying the Acceleration and Domain Specialisation The velocity metrics underscore the depth of this transformation. Healthcare’s adoption rate is 2.2 times faster than the broader economy, driven by the deployment of specialised, domain-specific AI tools.Across the industry, 22% of healthcare organisations have now deployed these domain-specific solutions, representing a massive seven-fold increase over the figures reported in 2024. This data validates the necessity for purpose-built, industry-specific AI models tailored to the clinical, regulatory, and technical complexity of healthcare workflows, contrasting sharply with the broader economy’s slower adoption of more generalised LLM applications. Adoption leadership is concentrated heavily among providers. Health systems are pioneering the transformation, demonstrating 27% adoption of specialised AI, significantly outpacing outpatient providers (18%) and payers (14%). This concentration of activity has fueled a thriving ecosystem of high-value start-ups, resulting in the creation of eight AI unicorns across key areas like medical documentation, Revenue Cycle Management (RCM), and payer operations—more than any other vertical AI category examined. Case Studies in Institutional Execution Leading health systems are making commitments that signal the institutionalisation of AI as a core strategic pillar: Kaiser Permanente: The successful, large-scale deployment of Abridge’s ambient documentation solution across 40 hospitals and over 600 medical offices serves as a crucial benchmark. This rollout, noted for being the largest generative AI implementation in healthcare history, demonstrates that large-scale, complex health systems can achieve unprecedented deployment speed when the strategic value proposition is sufficiently compelling and the technology is mature. Advocate Health: This organisation has adopted a systematic, portfolio approach to AI integration, evaluating more than 225 potential AI solutions before selecting 40 specific use cases for production deployment. These use cases span key areas including the largest deployment of Microsoft Dragon Copilot, advanced imaging tools like Aidoc and Rad AI, and AI integration into call centre operations. The organisation projects these initiatives will result in a documentation time reduction of more than 50%. Mayo Clinic: The institution’s commitment to AI is demonstrated by an investment exceeding $1 Billion across more than 200 projects over the coming years. This major investment signals a strategy that extends far beyond immediate administrative automation, explicitly targeting complex applications in diagnostics, patient care, and clinical decision support. The rapid deployment of administrative "quick win" tools is a deliberate strategy used by leading systems to build the necessary technical and compliance infrastructure, the "operational muscle", required for sustained AI integration. By securing early, measurable wins in lower-risk domains, these organisations are de-risking the complex internal political, technical, and change management landscape, establishing proven frameworks for AI governance and rapid deployment that will ultimately accelerate future investments into high-stakes clinical areas, as exemplified by Mayo’s substantial commitment. Capital Allocation Analysis: Deconstructing the $1.4 Billion Surge Provider Dominance and Expenditure Focus The distribution of the $1.4 Billion in AI spending clearly illustrates the acute pain points driving current market behaviour. Providers are the dominant purchasers, supplying $1 Billion (75%) of the total capital flow, driven by the urgent need to stabilise thin margins, mitigate administrative burdens, and combat significant post-pandemic staff shortages. The expenditure is heavily concentrated in the "Big Two" categories that offer the most immediate and tangible operational relief: Ambient Clinical Documentation: Accounting for $600 Million in spending, this is the largest single AI category. The primary value proposition is the reduction of physician burnout by automating the historically time-consuming process of note-taking and EHR population. Coding and Billing Automation (Back-Office RCM): This category commands $450 Million in spending. Its focus is on recovering lost revenue by automating complex coding workflows and mitigating claim errors and denials, offering a direct financial return on investment. The allocation of over $1 Billion to these two areas, documentation and RCM, confirms that immediate financial stability and staff retention are the paramount investment drivers in 2025. Purely clinical AI applications, while vital for the future, are often being funded by the efficiency savings generated through the successful deployment of these operational AI systems. This spending pattern is a direct reflection of economic distress compelling technological adoption, rather than solely a reaction to clinical breakthroughs. Emerging Hyper-Growth Categories: Unlocking New Budgets Beyond the dominant categories, AI is creating new markets by solving service gaps that were previously unaddressable by traditional software. These segments exhibit hyper-growth due to their potential to convert expensive, manual services dollars into scalable software revenue: Prior Authorisation: This process, widely regarded as healthcare's "most reviled administrative process," is also one of the largest opportunities for streamlining. AI has already created a $100 Million-plus market in this space, experiencing a rapid growth rate of +10x year-over-year. AI solutions augment or replace staff who traditionally spent hours on calls or filling out forms, compressing authorisation times from days to minutes. Patient Engagement/Call Centres: Focused on leveraging voice-enabled AI to augment staff and improve patient access, this segment represents a $100 Million-plus market. It exhibits the highest velocity growth, accelerating at +20x year-over-year. The rapid growth in Prior Authorisation and Patient Engagement (10x and 20x YoY, respectively) demonstrates that venture capital valuations are rewarding companies that successfully automate manual workflows. These solutions are generating new revenue streams by automating services that were never traditionally considered part of the IT budget, efficiently addressing the massive $740 Billion annual U.S. healthcare administration cost base. Procurement and Adoption Dynamics: The Bifurcated Marketplace Provider Speed: Urgency and Decisive Action The provider segment, comprising health systems and outpatient facilities, is demonstrating an unprecedented urgency in AI procurement. Health systems have reduced their average buying cycles by 18% (from 8.0 months to 6.6 months), while outpatient providers have seen an even greater improvement, shortening cycles by 22% (from 6.0 months to 4.7 months). This compression reflects a clear strategic alignment to rapidly capture operational gains and alleviate organisational pressure. Provider decision-making is governed by three primary criteria for selecting AI partners and solutions Maturity of technology: Prioritising production-ready solutions that demonstrate reliable performance at scale. Level of risk to patient care: Tools that do not directly interface with or expose patients to risk achieve faster approval and deployment timelines. Short-term value delivery: Focusing on quick wins and rapid ROI generation to maintain momentum and internal credibility. The willingness of organisations to pay a premium for trusted AI solutions, rather than prioritizing cost minimisation, underscores a strategic focus on de-risking operations and ensuring long-term reliability. Payer Deliberation: Caution and Risk Transfer In stark contrast to the acceleration observed among providers, the payer sector is exhibiting strategic caution. Payer procurement cycles have lengthened by 20%, increasing from 9.4 months to 11.3 months. Payers remain largely "AI-curious," confined primarily to piloting and internal experimentation. Their reluctance to move quickly into large-scale production deployments stems from a strategic concern: that increasing provider efficiency (e.g., faster RCM and billing submissions) will lead to a surge in claims volume and overall increased medical costs. Currently, payer AI spending is negligible ($50 Million) and focused predominantly on internal, generalised LLM applications, such as summarising clinical literature, rather than core workflow automation. This lengthening of payer cycles is interpreted as a short-term, defensive mechanism against the escalating efficiency of provider workflows. However, as provider adoption continues to accelerate, particularly in high-stakes, volume-driving areas like prior authorisation (growing 10x YoY), the operational and political pressure on payers to match this velocity will increase dramatically. This divergence creates a unique arbitrage opportunity for startups: by focusing on optimising workflows exclusively for the provider (where the capital and urgency reside), they effectively force the hand of the payer to eventually invest in counter-automation solutions to manage the claims influx. The pharmaceutical and biotech segments are following a different path, maintaining steady 10-month buying cycles. These companies are focused primarily on building proprietary models rather than adopting off-the-shelf vendor IT solutions. Comparative AI Procurement Cycles Stakeholder Segment Traditional IT Cycle (Months) AI Solution Cycle (Months) Change Adoption Stance Health Systems (Providers) 8.0 6.6 18% Acceleration Rapid Deployment of Production Systems Outpatient Providers 6.0 4.7 22% Acceleration Urgency to Capture Operational Gains Payers 9.4 11.3 20% Lengthening Deliberate, AI-Curious, Risk Mitigation Pharma/Biotech $\approx $10 $\approx$10 Steady Focused on Piloting/Proprietary Model Building The Competitive Landscape: Startups, Incumbents and Disruption Risk Generative AI Dominance by Challengers The introduction of generative AI has created a clear market dislocation: 85% of all generative AI spending in healthcare currently flows to AI-native startups, rather than established incumbents. This market disparity is attributed to a structural advantage held by challengers. Startups are unburdened by legacy technical debt and the bureaucratic inertia of larger organisations, allowing them to design products natively around sophisticated AI capabilities. This is vividly illustrated in the ambient scribing market, where AI-native companies like Abridge (30% market share) and Ambience (13% market share) have captured nearly 70% of the new generative AI market, effectively challenging the large incumbent Nuance’s DAX Copilot (33% market share). The Imminent Commoditisation of Point Solutions Despite the strong initial revenue capture by AI-native challengers, the market is already exhibiting signs of instability and commoditisation. The success of ambient scribes is tempered by a critical weakness: weak stickiness. Up to 67% of outpatient providers expect to switch their scribing vendor within three years, viewing the core technology as increasingly commoditised. Similarly, large health systems report being equally likely to switch as they are to remain with their current vendor. This significant churn pressure necessitates that successful startups immediately leverage their initial revenue lead to expand rapidly beyond mere documentation. Survival requires transitioning from a single-feature point solution to a comprehensive, integrated AI platform capable of solving multiple, adjacent workflow problems.This dynamic suggests that the current Generative AI market is functioning as a high-stakes screening process, where failure to expand functionality will likely result in acquisition by incumbents or extinction via commoditisation. The Incumbent Counter-Attack and the Trust Moat The major healthcare IT incumbents, including Epic, Oracle Health, and athenahealth, face real disruption risk from the rapid rise of AI-native challengers. Their initial AI offerings have largely been perceived as bolt-on features integrated into legacy platforms. However, incumbents retain powerful, enduring competitive advantages in distribution, deep integration, and, critically, customer trust. Despite the high revenue capture by startups, customers report a slight preference for purchasing critical, high-risk functions, such as coding, billing automation and clinical decision support (CDS), from their trusted EHR provider. The incumbent counter-strategy relies on leveraging this established trust for core clinical functions and integrating or acquiring successful point solutions as market commoditisation accelerates. The barrier to entry for a high-functioning, integrated, and regulatory-compliant RCM or CDS tool is extremely high, reinforcing the incumbent advantage in mission-critical systems. Strategic Funding Pathways: Converting Services Dollars to Software The Total Addressable Administrative Market The true scale of the opportunity for AI in healthcare is defined by administrative spend. Total U.S. healthcare administration spending reaches an estimated $740 Billion annually. This immense market, historically dominated by manual labour, dwarfs the traditional healthcare IT budget, which is estimated at $63 Billion.Targeting this services budget is the engine for future high-growth valuations. Dual-Path Budget Acquisition Strategy AI solutions are gaining budget through two fundamentally different, yet intertwined, paths: Augmenting Existing IT Spend (Capital Competition): This path involves selling intelligent modules that augment existing IT systems. Solutions in medical documentation and back-office RCM, which comprise approximately $38 Billion of existing IT spend, compete directly within the confines of established IT budgets. This strategy is about improving the efficiency of existing software and workflows, competing for a fixed pool of funds. Automating Manual Workflows (Capital Creation): This crucial path involves automating complex, labor-intensive workflows that were historically never part of the IT budget. By automating roles in areas like prior authorisation, these AI companies are effectively converting $740 Billion of annual services dollars, previously allocated to staff, into scalable software dollars. The automation of manual workflows (Path 2) is the engine of high-growth valuations because it represents capital creation. This approach generates new, substantial revenue streams by changing the underlying cost structure of healthcare delivery, offering a significantly stronger value proposition than simply competing for constrained IT budgets (Path 1). The success of companies automating complex processes like prior authorisation demonstrates that AI is fundamentally redefining the necessary staff component, reinforcing the urgency behind the 2.2x adoption rate observed among providers. The Frontier of Discovery: AI in Life Sciences and Biotech Proprietary Models and IP Strategy The adoption curve for life sciences and biotech companies is deliberately slower than that of providers, characterised mostly by piloting and experimentation. This sector's strategy is fundamentally focused on building proprietary defences rather than integrating off-the-shelf software. A significant 66% of pharmaceutical and biotech companies are prioritising the effort to build or fine-tune their own proprietary models, including developing foundation models of biology and drug discovery. This preference for internal intellectual property suggests that the key competitive advantage in pharma AI is tied directly to the access and proprietary structuring of unique, internal biological and trial data. These organisations perceive massive value in protecting and monetising their decades of internal data.The highest area of interest is R&D data analysis (63%), leveraging AI to accelerate the costly and time-consuming drug discovery lifecycle. Application Across the Development Lifecycle While R&D remains the core focus, life sciences organisations are strategically expanding AI use cases beyond laboratory functions and into operational areas across the product lifecycle Quality and Regulatory: This function shows the highest current adoption rate at 48%, reflecting the utility of AI in managing and ensuring compliance in rigid processes. Development Stages: Pre-clinical studies show 42% adoption, and clinical trials demonstrate 40% adoption, indicating the immediate value of AI in optimising experimental design and resource allocation. Operational Functions: Investment priorities also include medical affairs (40% adoption), manufacturing, and commercial operations. Life Sciences AI Adoption and Model Strategy Strategic Focus Area Adoption/Interest Rate (%) Strategic Implication Proprietary Model Building/Fine-tuning 66% Focus on IP creation; AI is a tool to monetize proprietary biological data. R&D Data Analysis 63% Primary focus for utilizing AI to accelerate the discovery phase. Quality and Regulatory 48% High priority for ensuring compliance and streamlining internal processes. Pre-clinical Studies 42% Leveraging AI to reduce the cost and time of early-stage experimentation. Conclusion and Forward-Looking Recommendations The Remaining Market Potential and Next Waves The healthcare AI moment has arrived, characterised by high-velocity adoption and substantial production investment. Despite the tripling of AI spending and unprecedented adoption rates, the report estimates that 80% of the total market remains untapped. This massive, latent opportunity provides a substantial runway for continued innovation and investment over the next decade. The next waves of strategic growth will be defined by companies that successfully automate the remaining segments of the services economy and deepen their functional integration: Voice-Enabled AI: Expanding the use of AI beyond mere clinical documentation into complex patient engagement, virtual assistants, and interaction interfaces. Prior Authorisation at Scale: Fully realising the potential of the +10x YoY growth category by fundamentally solving the systemic friction of this administrative burden, thereby converting a greater share of the $740 Billion administrative services budget. Disintermediation Platforms: Companies that transcend single point solutions to establish themselves as the essential AI orchestration layer, operating between the clinician workflow and the core EHR system. Strategic Considerations on Risk and Trust A non-negotiable factor governing scale remains trust. Healthcare organisations explicitly confirm their prioritisation of trusted AI solutions, viewing the cost of a premium solution as less severe than the potential costs associated with operational failure, reputational damage, or patient harm. This emphasis on trustworthiness dictates that solutions impacting patient safety will continue to face deeper scrutiny and longer timelines than administrative tools. The high-velocity adoption currently observed in administrative, low-risk domains serves as a crucial, market-driven mechanism for setting deployment standards and building confidence. This established framework for rapid, low-stakes implementation is the necessary blueprint for how high-stakes Clinical Decision Support (CDS) tools will eventually scale, once regulatory and reliability standards reach the threshold of institutional acceptance. Systemic Transformation: The Future of Healthcare Intelligence The long-term winners in the healthcare AI ecosystem will not be defined by mere task automation, such as simple scribing, but by their ability to build a comprehensive system of intelligence that enables reasoning, creation, and prediction for the enterprise. This involves moving past Layer 2 (Data preparation) in the modern AI stack and becoming proficient in Layer 3 (Deployment and Orchestration).Successful startups must transition to become the preferred orchestration layer—the operational hub for AI, to sustain market share and truly disintermediate incumbents, rather than remaining commoditised feature providers. Ultimately, the accelerated adoption rate of AI in healthcare signals a permanent, structural transformation in the industry’s labor market and operational model. By efficiently converting the $740 Billion of services dollars into scalable software revenue, AI is not only lowering administrative costs but is fundamentally redefining staff roles, offering the potential to free up clinicians for higher-value, direct patient care. This re-allocation of resources and capital is the most profound long-term implication of the AI inflection point demonstrated in the 2025 report. Source: https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/ Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The NHS Productivity Imperative: Strategic Analysis of the Microsoft 365 Copilot Trial and the Path to National Digital Transformation Source: https://www.gov.uk/government/news/major-nhs-ai-trial-delivers-unprecedented-time-and-cost-savings Section 1: The Strategic Context of the NHS Productivity Challenge The Analogue-to-Digital Mandate and the 10 Year Health Plan The National Health Service (NHS) is currently undergoing a fundamental transformation, mandated by the government’s 10 Year Health Plan, which prioritises the shift from analogue to digital operations. This strategic commitment frames AI adoption not merely as an efficiency measure, but as a critical requirement for securing the NHS’s future financial sustainability. Key objectives of this ambitious plan include moving "from bricks to clicks" and granting patients control over a single, secure and authoritative account of their health data, a unified patient record, which facilitates more coordinated, personalised, and predictive care models. Crucially, the government has established a mechanism to enforce continuous digital investment, requiring all NHS organisations, for the first time, to reserve a minimum of 3% of their annual expenditure specifically for one-time investments in service transformation. This policy is designed to overcome historical underinvestment in technology and accelerate the translation of proven innovations, such as the AI trial results, into national practice. This mandated capital expenditure mechanism ensures that the necessary financial foundation exists to integrate large-scale digital tools like Microsoft 365 Copilot, providing a sustained route away from dependence on archaic or legacy IT systems. The modernisation effort is thus inextricably linked to structural fiscal sustainability. Quantifying Policy Success: Exceeding Productivity Targets The initial phase of digital integration has already yielded measurable successes against national policy benchmarks. Government data confirm that NHS productivity for acute trusts increased by 2.7% between April 2024 and March 2025. This increase significantly surpasses the government's strategic objective of achieving a 2% year-on-year productivity target established within the 10 Year Health Plan. This productivity boost is attributed partly to the focused application of technology and artificial intelligence (AI), alongside targeted efficiency initiatives in core clinical areas, including elective care, outpatient reform, and urgent and emergency care. While the 2.7% metric is a system-wide achievement across acute trusts, the concurrent success of the Copilot trial across 90 organisations suggests that AI is serving as a crucial digital underpinning for broader efficiency gains. The AI technology is not an isolated initiative; rather, it functions as an accelerant, making traditional clinical reforms more effective by reducing the administrative friction that traditionally slows down complex care pathways. The successful demonstration of productivity gains across the system indicates that the strategic focus on technology is beginning to pay dividends, aligning with the mandate to drive efficiency and cut waste. The true long-term value of the AI initiative lies not just in staff minutes saved, but in its measurable contribution to targets like improving the percentage of patients waiting no longer than 18 weeks for treatment. The Administrative Burden as a Primary Target for AI Intervention The adoption of AI productivity tools is directly motivated by the significant administrative burden placed upon NHS staff. Health innovation leadership, including clinicians, recognises the deep frustration caused by "archaic technology that makes day-to-day tasks painstakingly long". The core mandate of the Microsoft 365 Copilot trial was explicitly to target this administrative friction, thereby freeing up staff "to focus on what they want to be doing - treating patients". The highly successful initial adoption of M365 Copilot is predominantly anchored in its application to generic "knowledge-worker tasks" across the organisation. These tasks include high-volume, non-clinical documentation such as handling Freedom of Information requests, documenting critical incidents, and automating Human Resources inquiries. This strategic focus on reducing friction in non-clinical documentation minimises exposure to immediate clinical risk, establishing M365 Copilot as an optimal, low-risk, first-wave model for large-scale generative AI deployment within the NHS. Section 2: Quantitative Validation and Economic Projections of the Copilot Trial The results of the large-scale AI pilot provide robust quantitative validation for the strategic decision to integrate generative AI into NHS workflows, demonstrating unprecedented potential for time and cost recovery. Methodology, Scale and Core Savings Metric The Microsoft 365 Copilot trial represents the largest artificial intelligence trial of its kind globally within the healthcare sector, involving more than 30,000 NHS staff across 90 different NHS organisations. The sheer scale of the trial provides a statistically powerful and real-world data set for projecting national rollout benefits, significantly strengthening the viability claims compared to outcomes derived from smaller, isolated technology pilots. The core metric derived from the pilot was an average productivity gain of 43 minutes or more saved per staff member per day. When extrapolated, this daily saving equates to the recovery of five weeks of time per person annually. Decomposition of Administrative Time Savings When aggregated across the entire workforce, the projected savings are substantial. Results from the trial indicate that a full national rollout could save up to 400,000 hours of staff time every month, equating to millions of hours recovered annually. These recovered hours are intended to enable staff to allocate their time more effectively toward frontline patient care. Analysis of the time savings reveals which specific organisational inefficiencies the AI is most effectively addressing. The decomposition of saved time shows significant mitigation of communication overhead, a recognized systemic inefficiency within the NHS. Quantified monthly savings projections include approximately 83,333 hours saved in note-taking. Furthermore, the largest documented saving comes from utilising Copilot to summarise long and complex email chains, saving up to 271,000 hours monthly. This high saving in email processing reflects a systemic pathology within the NHS workflow: communication overhead is massive, with over 10.3 million emails and more than one million Teams meetings occurring each month. By automating the digestion and synthesis of this traffic, the AI tool is reducing the cognitive burden required to navigate organisational complexity, suggesting that the value extends beyond simple secretarial productivity to improving overall system-level communication velocity and coordination. Financial and Economic Projections (ROI Modelling) The time savings translate directly into significant economic opportunities. The NHS projects that the technology, based on a user base of 100,000 staff, could save millions of pounds every month, potentially reaching "hundreds of millions of pounds in cost savings every year". The government has explicitly mandated that these cost savings must be redirected and reinvested in "directly improving patient care and frontline services". These projected cost savings are modeled on the theoretical reduction in operational expenditure derived from the immense hours recovered. However, the lack of robust, empirical data confirming how the saved time is repurposed (as detailed in Section 6) introduces a critical analytical consideration. If the time saved is absorbed by increased demand rather than reducing administrative headcount or workload, the financial benefits may materialise as increased capacity utilisation within the existing budget structure, rather than quantifiable reductions in operational cost. Therefore, the successful realisation of these projected hundreds of millions in savings necessitates developing a robust financial tracking and audit mechanism, aligned with the 3% mandated transformation reserve, to ensure efficiency gains are realised as verifiable taxpayer value. The projected benefits are summarised below: Metric Scope Finding / Projection Source Daily Time Saved (Per Staff Member) Trial (90 NHS Orgs) 43 minutes or more NHS Annual Time Saved (Per Staff Member) Trial Projection 5 weeks annually NHS Total Staff Hours Saved National Rollout Projection 400,000 hours per month NHS Administrative Savings (Email Summary) National Rollout Projection Up to 271,000 hours per month NHS Acute Trust Productivity Increase (YOY) April 2024 – March 2025 2.7% (Exceeds 2% target) NHS Projected Annual Cost Savings National Rollout (100k users) Hundreds of millions of pounds NHS Section 3: Strategic Investment, Digital Infrastructure, and Scalability Impediments The transition from pilot success to ubiquitous national service hinges entirely on the ability to overcome systemic infrastructure deficits and align capital expenditure with strategic needs. Capital Allocation and the 3% Transformation Mandate Financial commitment is substantial: for the 2025/26 financial year, NHS England has allocated £596 million specifically to drive digital transformation and enhance operational capabilities, with an additional £400 Million earmarked for technology initiatives focused on improving productivity. This tactical funding is supported by a broader commitment of up to £10 Billion for NHS technology and digital transformation by 2028/29. The £400 Million productivity fund is a direct, dedicated financial instrument designed to scale successes demonstrated in trials like Copilot. However, the most strategically significant policy lever is the government's requirement that NHS organisations reserve at least 3% of their annual expenditure for service transformation investments. This mandate represents an essential, long-term cultural shift away from reliance on episodic national grants toward continuous, sustained capital investment necessary for digital maturity. This structure ensures that resources are consistently available at the Integrated Care Board and trust level to absorb and embed transformative tools, sustaining momentum beyond initial grant cycles. The Critical Infrastructure Deficit (Digital Debt) The realisation of the potential benefits is critically dependent on overcoming the extensive digital debt across the NHS. Expert analyses warn that successful AI deployment is entirely conditional on possessing the "right digital infrastructure". Existing barriers to integration include deep-seated issues such as legacy systems, infrastructure gaps, poor or incompatible platforms, and the simple lack of "reliable WiFi, interoperable and secure platforms". This is compounded by the fact that over one in four public sector systems still operate on legacy technology, a figure that escalates to 70% in certain NHS trusts. The deployment of sophisticated generative AI, such as M365 Copilot, requires stable, high-speed bandwidth and robust cloud connectivity to function optimally. If provider organisations still face basic connectivity hurdles like unreliable WiFi, deploying complex, cloud-dependent AI tools is strategically unsound. This creates a high risk of a "digital divide" within the NHS: high-performing and financially secure trusts will gain exponential productivity advantages, while digitally immature trusts, hindered by legacy IT, will struggle to integrate the technology, potentially exacerbating existing health inequalities. Therefore, the strategic allocation of the £400 Million productivity fund and the 3% mandated spend must prioritise foundational IT modernisation, not just software licensing, to ensure equitable access and consistent function across the entire NHS. The Interoperability Challenge and Ecosystem Integration For long-term viability, any new AI tools must ensure seamless interoperability with the wider NHS digital systems and frameworks. This includes achieving compatibility with foundational frameworks such as FHIR standards and SNOMED CT, and possessing the infrastructure capability to securely handle the massive volumes of patient data generated in a healthcare setting. The NHS is simultaneously driving the implementation of the Federated Data Platform (FDP). While M365 Copilot operates primarily in the administrative productivity layer, the strategic ambition is a move toward "Agentic healthcare," where multiple specialised AI assistants collaborate, one interpreting unstructured notes, another pulling data from clinical systems. This future state necessitates absolute compliance with interoperability standards. The Microsoft productivity layer must coexist and eventually integrate with the larger clinical data landscape, which already involves major vendors of Electronic Health Records (EHRs) such as Epic and Cerner (Oracle Health), and infrastructure support from rival hyper scalers like Google Cloud and Amazon Web Services (AWS). The long-term architectural strategy must ensure modularity to facilitate easy upgrades and adaptation to future healthcare technologies. Section 4: Regulatory and Governance Framework for Safe AI Deployment Addressing the regulatory environment is crucial for ensuring public trust and long-term sustainability, particularly through clear differentiation between administrative AI and medical AI. Classification of LLMs: Productivity vs. Medical Device A key strategic advantage of the M365 Copilot adoption pathway is its clear focus on administrative support.Because the tool automates email summarisation and document generation, it likely bypasses the classification as an AI as a Medical Device (AIaMD) by the MHRA, allowing for a comparatively faster, large-scale deployment to address widespread administrative friction. However, the regulatory pathway changes rapidly when AI nears the point of care. Microsoft has also launched Dragon Copilot in the UK, a clinical AI assistant that utilises ambient voice technology to record consultations in real-time and translate them into structured clinical notes. Early evidence suggests this tool can save over five minutes per consultation while improving documentation quality. Because Dragon Copilot actively influences clinical documentation, it operates within the medical regulatory space. Such tools must undergo stringent scrutiny, potentially utilising the AI Airlock regulatory sandbox and adhering to the Evidence Standards Framework (ESF) for digital health technologies. This regulatory divergence is a strategic advantage for initial high-volume deployment of M365 Copilot, but the NHS must rigorously maintain a strict operational boundary between M365 Copilot and clinical AIaMD to prevent the inadvertent clinical use of administrative tools, which carries safety and liability risks. Data Governance, Privacy and Public Trust The deployment of AI systems across healthcare intrinsically involves the use of patient data, raising perennial issues concerning data quality, accessibility, and patient privacy. Health organisations are required to inform patients how their confidential information is used and must honour the patient's right to request their information not be used for certain purposes, such as marketing or insurance. Establishing and maintaining public trust is foundational to digital transformation efforts. The procurement of the Federated Data Platform (FDP) through Palantir ignited significant controversy, highlighting a pre-existing "trust deficit" regarding the commercialisation and usage of NHS data. To ensure public acceptance of the Copilot rollout, NHS England must clearly and transparently communicate the data governance protocols. This includes the assurances provided by the vendor regarding enterprise-grade security, the commitment that prompts and responses are never used to train the underlying models, and that access is strictly governed by existing Microsoft 365 permissions and sensitivity labels. This strong communication strategy is necessary to differentiate the productivity layer's data handling from large-scale, population-level data sharing initiatives. The Role of the AI Assurance Ecosystem The UK government insists that AI must be developed and deployed in a "safe, responsible way". AI assurance is recognised as a key pillar of broader AI governance, offering the necessary guardrails to operationalise regulatory principles. The successful integration of AI requires mitigating staff skepticism and addressing uncertainty regarding accountability and liability, issues that have hindered previous technology projects. This mandates the institutionalisation of a robust governance and audit function that operates throughout the deployment lifecycle. Clinicians require appropriate education concerning the impact and limitations of algorithms. This assurance ecosystem must provide objective proof that the technology works as intended and safely manages risk. Effective assurance protocols will directly address staff concerns about AI potentially "making decisions" without appropriate clinical oversight, thereby fostering confidence in the technology and accelerating adoption. Section 5: Strategic Risk Assessment: Vendor Dynamics and Commercial Leverage Deep partnerships with hyper scalers like Microsoft, while delivering immediate results, introduce complex long-term commercial and strategic risks that must be proactively mitigated, primarily focusing on vendor dependency. Vendor Lock-in and Long-Term Cost of Ownership (TCO) While the NHS uses its "collective buying power to secure market-leading products at reduced cost for taxpayers", relying too heavily on a single vendor for AI and cloud services can lead to debilitating vendor lock-in. The convenience of discounted pilots, such as the one described, can quickly transform into expensive long-term contracts with limited leverage. This loss of flexibility can result in accumulating costs over time, including high support fees and mandatory upgrades that may eventually surpass the initial investment. Given the rapid evolution of generative AI, where the landscape is evolving fast and new LLMs are constantly being released, committing early to Microsoft’s M365 ecosystem risks limiting the NHS's ability to capitalise on future breakthroughs from competitors. The financial implication is not just increased licensing fees, but the strategic loss of the freedom to innovate by becoming perpetually dependent on proprietary vendor formats.The NHS Commercial team must proactively balance the immediate productivity gains against this long-term TCO, demanding modular architecture and open standards to maintain competitive procurement leverage. Ecosystem Diversity and Commercial Strategy The NHS England Commercial Directorate recognises the danger and is explicitly committed to "further diversifying our supplier ecosystem and increasing opportunity for innovation and improved value for money". The UK government is also entering partnerships with competing hyper scalers, such as Google Cloud, specifically to help public sector organisations move away from archaic, high-cost legacy technology, thereby improving the government’s bargaining power. The commercial relationship with Microsoft for Copilot (productivity) must therefore be seen alongside other critical Big Tech contracts, such as the FDP awarded to Palantir and infrastructure agreements with Google and AWS. The diversification strategy is a necessary countermeasure to vendor lock-in. Effective strategic sourcing means utilising the NHS's immense market clout to demand interoperability, predictable long-term pricing, and adherence to open standards from all major technology partners. Section 6: The Clinical Reallocation Imperative: Translating Savings into Care The primary political and clinical justification for this large-scale AI investment is improved patient care. This section critically examines the weak empirical link between time saved and time subsequently repurposed for frontline duties. The Savings-to-Care Translation Gap The policy goal is unambiguous: for saved time to be "spent on directly improving patient care and frontline services". However, there is a significant empirical gap in the literature regarding how time freed up by technology is subsequently used. A rapid review found that less than 1% of studies concerning staff time saved by digital technologies tracked how that time was subsequently allocated, concluding that benefits are often simply assumed rather than empirically supported. The risk is that the "unprecedented savings" translate into an "unprecedented assumption." Simply recovering 43 minutes daily per staff member does not automatically translate into 43 minutes of direct patient care. In highly pressurised clinical environments, freed capacity is often absorbed by uncaptured administrative tasks, addressing backlogs, or increased demand, a phenomenon commonly referred to as "work creep". This outcome risks staff perceiving the AI merely as a tool to increase their expected output rather than reduce burnout or demonstrably improve quality of care. To validate the overall policy and ensure the return on investment, NHS England must implement mandatory, quantitative metrics—not just qualitative feedback—to audit how staff time is repurposed, linking saved hours directly to defined clinical outcomes, such as reduced wait times or improved documentation quality. Workforce Readiness and Change Management The transition to a digitally enabled NHS is slowed not only by infrastructure deficits but also by challenges related to workforce readiness, talent shortages, and operational capacity for change. Earlier attempts at AI integration faced considerable friction due to staff skepticism, difficulties in gaining governance approvals, and inadequate training that failed to address complex issues of decision-making, safety, and liability. Successful AI adoption is fundamentally driven from the "wards and offices up, not from the Board down".Scaling M365 Copilot requires comprehensive training that moves beyond basic application usage to addressing complex issues of decision support and accountability. Furthermore, the deployment must mitigate "change saturation," recognising that busy services struggle to prioritise new technology alongside core clinical pressures. Dedicated change management and robust training protocols are essential to maximise the 400,000 hours of projected time savings and ensure the workforce is prepared to adopt and integrate the technology effectively. NHS 10 Year Plan Priority Specific Success Measure (March 2026) Copilot/AI Contribution Alignment Evidence for Contribution / Risk Mitigation Reduce time people wait for elective care Improve % of patients waiting no longer than 18 weeks (target 65%) Indirect: Frees clinical staff for direct intervention and planning. Saved admin time (400,000 hours projected) redirected to care. Risk: Repurposing must be mandatorily audited. Live within the budget allocated, reducing waste Deliver a balanced net system financial position Direct: Achieves mandated efficiency improvements and cost reduction. Potential for hundreds of millions in cost savings annually. Mitigated by: 3% mandated transformation investment. Improve A&E waiting times & UEC Minimum 78% of patients admitted, discharged, or transferred within 4 hours Indirect: Improves rapid internal communication and documentation workflow. Email summarisation reduces administrative bottleneck for clinicians and improves communication velocity. Shift from analogue to digital Making full use of digital tools to drive the shift Foundational: Establishes a major cloud-based Gen AI footprint. Trial success proves immediate ROI potential of leveraging existing M365 investment. Challenge: Must overcome legacy IT and WiFi deficits. Section 7: Strategic Recommendations for Full National Scale-Up The success of the Microsoft 365 Copilot trial provides a compelling proof point for the NHS digital transformation strategy. To capitalise on the projected time and cost savings while mitigating the identified systemic risks, the following mandates are essential for achieving full national scale-up. Mandate Foundational Digital Investment First Prioritise the strategic allocation of the £400 Million productivity fund and the 3% mandated capital expenditure toward foundational digital resilience, including network upgrades, reliable WiFi, secure platforms, and interoperable data pipelines. Generative AI cannot function optimally on infrastructure where up to 70% of certain trusts still rely on legacy technology. Foundational investment ensures equitable readiness across all Integrated Care Boards before blanket software rollout, thereby mitigating the risk of creating a critical digital divide within the NHS. Establish a Robust "Savings-to-Outcome" Audit Framework Implement mandatory auditing protocols to empirically track and quantify how administrative time saved is allocated to high-value clinical or patient-facing activities, thereby closing the empirical "repurposing gap". This mechanism links the technology return on investment directly to improvements in core clinical priorities, such as efficiencies in elective care and urgent care targets, validating the premise that efficiency gains lead to verifiable clinical benefit and transparent taxpayer value. Enforce Modular, Competitive, and Auditable Procurement Future procurement involving major hyper scalers must prioritise modular architecture, FHIR/SNOMED CT compliance and competitive renewal clauses to aggressively mitigate vendor lock-in risk. The collective buying power of the NHS must be leveraged to secure contracts that demand interoperability and transparent, long-term pricing, ensuring dependency on one vendor for productivity does not compromise the broader NHS ambition to diversify its supplier ecosystem and maintain independent control over core data assets (e.g., FDP requirements). Institutionalise Regulatory Clarity for AI Usage Clearly define and communicate the regulatory boundaries between productivity LLMs (M365 Copilot) and AI as a Medical Device (AIaMD, e.g., Dragon Copilot) to all NHS staff. This minimises clinical risk stemming from staff using administrative tools for clinical decision support. Concurrently, comprehensive governance frameworks must be institutionalised for real-world clinical effectiveness monitoring and mandatory safety reporting. This approach builds confidence in the regulatory ecosystem (MHRA/DTAC) and ensures accountability remains clear as AI integration deepens. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

What is the MHRA’s AI Airlock? Can the UK be a leader in the safe regulation of Ambient VoiceTechnologies? What is the MHRA’s AI Airlock? The MHRA's AI Airlock is a regulatory sandbox for Artificial Intelligence as a Medical Device (AIaMD) products in the UK, launched by the Medicines and Healthcare products Regulatory Agency (MHRA). Its main purpose is to: Identify and address novel regulatory challenges posed by evolving AI medical devices. Provide a safe, controlled environment for manufacturers to test and evaluate innovative AI tools in real-world or simulated settings (often in collaboration with the NHS and Approved Bodies). Accelerate the safe adoption of effective AI in healthcare by working collaboratively with innovators and regulators early in the development process. Gather in-depth insights from the testing of real-world products to inform the MHRA's future regulatory frameworks and guidance for AIaMD. Essentially, it's a dedicated program to ensure that cutting-edge AI technologies are safe, effective, and can be brought to patients quickly by establishing clear, robust, and agile regulatory pathways. The Regulatory Vanguard: Assessing the MHRA AI Airlock and the UK’s Potential for Leadership in Ambient Voice Technology Governance Strategic Context: The UK’s Principles-Based Approach to AIaMD Regulation The governance of Artificial Intelligence as a Medical Device (AIaMD) presents unique challenges related to algorithmic adaptivity, transparency, and assurance of continuous safety. The UK’s regulatory approach to this domain is strategically defined by a commitment to agility and innovation, leveraging existing sectoral regulators rather than relying on monolithic, preemptive legislation. The Policy Divergence: Agility vs. Prescription in Global AI Governance The foundation of the UK’s ambition is laid out in its National AI Strategy, which aims to establish the country as a "global AI superpower" by fostering "the most trusted and pro-innovation governance framework". This philosophical stance emphasises a context-sensitive, iterative approach that allows for adaptation by specialised regulators, such as the Medicines and Healthcare products Regulatory Agency (MHRA). This model deliberately contrasts with the comprehensive and prescriptive legislative approaches adopted in other major jurisdictions, notably the European Union’s AI Act. The strategic decision is driven by a mandate to avoid introducing "new rigid and onerous legislative requirements" that could potentially impede the rapid advancement of AI innovation. The UK framework rests on five cross-sectoral principles, intended to guide the development and deployment of AI systems across all regulated industries: safety, security and robustness; appropriate transparency and explainability; fairness; accountability and governance; and contestability and redress. By delegating the interpretation and operationalisation of these high-level principles to expert sectoral bodies, the UK hopes to maintain greater flexibility in managing sector-specific risks. This decentralised, principles-based model, however, carries an inherent structural tension. While it grants high operational flexibility, it simultaneously shifts the burden of interpreting these broad principles into concrete, technical compliance requirements onto the regulated manufacturers. This regulatory uncertainty can, in the initial stages, introduce friction for developers seeking market authorization. The central mechanism designed to mitigate this risk, translating conceptual principles (like Fairness and Accountability) into empirical, sector-specific technical requirements (such as validation protocols for specific datasets or robust post-market surveillance methods) is the MHRA’s AI Airlock. The Airlock thus functions as the essential, agile bridge between high-level policy ambition and pragmatic regulatory implementation. The MHRA’s Mandate and the AIaMD Change Programme As the regulator for medical products in UK health and social care, the MHRA holds a critical position in ensuring patient safety. Where AI is utilised for a medical purpose, it is highly probable that it falls within the scope of a general medical device, necessitating compliance with the UK Medical Devices Regulations 2002.The MHRA’s dedicated Software Group is responsible for the oversight of Software as a Medical Device (SaMD) and AIaMD, engaging in activities ranging from technical file reviews and post-market surveillance to assisting manufacturers with pre-market enquiries. To address the rapidly evolving nature of digital technology, the MHRA launched the Software and AI as a Medical Device Change Programme Roadmap. This programme outlines an extensive three-year project dedicated to driving regulatory reforms across the entire software and AI medical device life cycle. Crucially, this reform addresses specific challenges posed by AIaMD, focusing on issues of transparency, including explainability and interpretability, and the challenge of adaptivity, which concerns the retraining and continuous evolution of AI models. The explicit emphasis on 'adaptivity' highlights the agency’s recognition of the challenges presented by Continuously Learning Adaptive Medical Devices (CLAMDs). Traditional regulatory frameworks rely on assessing a device's performance at a fixed point in time ("lock-in-time" assessment). CLAMDs, however, change their function or performance characteristics based on real-world data. This dynamic quality inherently challenges fixed pre-market validation requirements, necessitating a fundamental shift toward regulating the entire algorithmic life cycle. The complexity introduced by adaptivity is precisely the regulatory gap that the MHRA is leveraging the AI Airlock to close, by gathering empirical evidence on how to safely manage algorithms that continuously evolve after deployment. The MHRA AI Airlock: A Pioneering Regulatory Sandbox for AIaMD The MHRA AI Airlock represents the practical, operational manifestation of the UK’s agile, principles-based AI strategy within the health sector. It is designed to proactively address the technical and regulatory friction points caused by AI's rapid advancement. A. Definition, Necessity and Operational Methodology The AI Airlock is the MHRA’s first regulatory sandbox for AIaMD products, officially launched in pilot form in Spring 2024. Its purpose is not to grant market approval, but rather to serve as a collaborative environment dedicated to identifying and accelerating solutions to the novel regulatory challenges presented by AIaMD, using real-world products and specific case studies. This initiative is deeply collaborative, drawing expertise from various stakeholder groups essential for governing the AI life cycle: internal MHRA technical specialists, UK Approved Bodies (coordinated through Team AB, launched February 2024, to promote consistent regulatory interpretation), the NHS, the NHS AI Team, and the Department of Health and Social Care. Significantly, the Information Commissioner’s Office (ICO) also supports the Airlock, offering specific referral services and advice to applicants concerning data protection by design. The Pilot Programme, which ran from Spring 2024 to April 2025, followed a rigorous, structured four-step methodology to investigate regulatory gaps: Orientation: A thorough situation assessment to understand the specific technologies under investigation and their relevant regulatory context. Plan: Regulatory gap review conducted in collaboration with the developers, culminating in the development of a tailored test plan. Test: Execution of testing in simulation, virtual, real-world, or hybrid environments, allowing for deep analysis of regulatory gaps. Review: Synthesis of all findings and the formulation of recommendations. The Airlock program is structured to address increasingly complex challenges across its phases. Phase Duration Core Objective Target Regulatory Challenges (Examples) Key Data Sources Pilot Phase (Phase 1) Spring 2024 – April 2025 Methodology testing; identify baseline regulatory gaps using products from four innovators (e.g., Philips, AutoMedica, OncoFlow, Newton's Tree). Risk Management, Validation of Text-Based Data (LLMs), AI Non-Determinism, Explainability, Post-Market Surveillance. UK Phase 2 March 2025 – March 2026 Reduce regulatory uncertainty; contribute to future guidance; focus on complex adaptive AI and implementation. Scope of Intended Use Extension (Evolving AI), AI-Powered Diagnostics Regulation, Implementing Robust Post-Market Surveillance. UK Linking Airlock Outputs to Future Policy The strategic value of the AI Airlock lies in its mandated purpose to directly inform future policy. The in-depth, technical insights gathered from testing real-world products and methodologies serve as the empirical data required for robust policy formulation. The pilot programme culminated in comprehensive reports detailing the regulatory sandbox methodology, the results of the case studies, and lessons learned from the independent evaluation. While these reports do not constitute formal statutory guidance, they are essential deliverables intended to inform subsequent Airlock phases and, critically, future MHRA guidance and policy in the longer term. The ultimate policy link is through the MHRA's National Commission into the Regulation of AI in Healthcare. The in-depth findings from the Airlock are explicitly intended to inform the recommendations delivered to this high-level body, which synthesizes advice from clinicians, regulators, and technology companies. This structured pathway ensures that regulatory reform is evidence-based and closely reflects the technical realities and clinical deployment issues uncovered in the sandbox environment, aligning the UK's aspirational principles with practical regulatory solutions. Findings from the AI Airlock Pilot: Identification of Critical Regulatory Gaps The AI Airlock pilot demonstrated the effectiveness of the sandbox methodology by successfully identifying several foundational regulatory gaps that impede the safe and effective deployment of complex AIaMD. These gaps varied across use cases but centered on core challenges inherent to generative and adaptive AI systems. The Validation Crisis of Generative AI (LLMs) One of the most profound regulatory gaps identified during the pilot related to the challenge of validating systems underpinned by Large Language Models (LLMs). The pilot specifically highlighted difficulties in the validation of text-based data from LLMs, noting the recurring issues of AI errors, inaccuracies, and non-determinism. Non-determinism, the inability of an AI system to consistently produce the exact same output from identical input data, is a critical conflict with established medical device compliance requirements. Traditional medical device validation mandates that a device's performance specifications must be reliably characterized and guaranteed before market entry. When an LLM-based system, such as an Ambient Voice Technology scribe, exhibits non-deterministic behaviour, the manufacturer cannot fulfill the regulatory obligation to consistently guarantee the system's defined performance specifications. This lack of predictable performance makes compliance demonstration using current, traditional rules fundamentally inadequate. The Airlock's empirical confirmation of this specific technical regulatory failure establishes a clear need for the MHRA to move toward a new paradigm that emphasises continuous statistical performance monitoring and bounds of acceptable variation, rather than relying on traditional fixed, rules-based validation procedures. Managing Evolving AI and Scope of Intended Use Extension Beyond the challenge of initial validation, the pilot and subsequent phases address the regulatory complexities introduced by continuously evolving AI, the 'adaptivity' challenge. AI systems operate by inferring patterns, making it difficult to fully explain the intent or logic behind an outcome. Phase 2 of the AI Airlock, currently underway, is deliberately structured to focus on three key areas of friction: managing evolving AI applications, effectively regulating AI-powered diagnostics, and implementing robust post-market surveillance (PMS) for AI medical devices. Multi-environment candidates, such as TORTUS, an evolving clinical AI assistant designed to reduce administrative burden, are participating to test the real-world implications of regulatory requirements. The challenge of intended use extension for evolving AI is paramount. An AI medical device's risk classification is intrinsically linked to its intended function. If a device is allowed to continuously adapt or add functionality post-market, its initial pre-market classification may become obsolete, potentially escalating its risk class (e.g., from Class I to Class IIa). The regulatory approach must recognize that a device’s risk profile is now dynamic. If an adaptation suggests management pathways or diagnostic interpretations, it moves instantly from a low-risk administrative tool to a higher-risk clinical decision support system. The MHRA’s focus on linking 'post-market surveillance' to 'intended use extension' in Phase 2 indicates a clear regulatory objective: to establish PMS not merely as a defect reporting obligation, but as a continuous, mandated quality management and risk classification checkpoint. This approach enables the regulator to oversee and potentially restrict algorithmic evolution if the resulting risk exceeds the bounds of the original market authorization. Ambient Voice Technologies (AVT): A Critical Test Case for Regulation Ambient Voice Technologies (AVT), often referred to as AI scribes, are systems that utilize AI—frequently based on Large Language Models—to capture and process spoken conversations during clinical interactions, subsequently automating tasks such as drafting clinical notes and referral letters.15 Given their dependence on LLMs and their close integration into high-stakes clinical workflows, AVT represents a crucial test case for the efficacy of the UK’s agile regulatory strategy and the findings of the AI Airlock. Functional Profile and Regulatory Classification The utility of AVT is significant, offering potential positive impacts on financial performance and, critically, human outcomes by mitigating clinician burnout through the automation of time-consuming documentation.Faster, automated documentation also leads to improved operational efficiency and patient throughput. The regulatory classification of AVT hinges entirely on the scope of its intended use, aligning with the UK’s risk-based medical device framework. Class I (Low Risk): If the AVT function is strictly limited to summarisation and creating templated information intended for clinicians to use as part of an individual’s health record. These devices are generally self-declared medical devices in the UK. Class IIa or Higher (Medium/High Risk): If the AVT provides any functionality that extends to diagnosis, proposing a management plan, referral calculation, or other functions beyond simple transcription or summarisation, the device classification elevates, mandating approval by an Approved Body. This regulatory boundary is highly susceptible to the non-deterministic nature of LLMs confirmed by the Airlock. A product marketed as a Class I summariser is inherently at risk of generating diagnostic text or subtly suggesting management plans due to LLM 'hallucination' or unintentional function creep, thereby operating outside its self-declared regulatory status and potentially introducing unassessed risk into the clinical setting. The Central Governance Principle: Human-In-Command (HIC) The UK legislative and regulatory approach for adopting AVT emphasises stringent control mechanisms. Any health service provider, such as NHS Wales, choosing to adopt AVTs must adhere to existing UK legislative and regulatory requirements, including those set out by the MHRA. The paramount safety principle is the Human-in-Command (HIC) mandate. AVTs must not be used as autonomous tools but operate under strict human supervision. The clinician retains full and ultimate responsibility for the accuracy of the records, for validating the AVT outputs, and for ensuring the clinical notes align with the legal and professional scope for registered professionals. Adoption also requires mandatory compliance with NHS procurement standards, specifically the NHS Digital Technology Assessment Criteria (DTAC).Key compliance pillars include: evidence of compliance with DCB0129 (a clinical safety standard), the appointment of a professionally registered Clinical Safety Officer (CSO), GDPR compliance, and a signed-off Data Protection Impact Assessment (DPIA) by the deploying organisation. The HIC principle functions as the legal backstop for accountability. However, expert analyses have identified a significant socio-technical risk that undermines this safeguard: reliance bias. While clinicians may be vigilant against errors initially, over time they become accustomed to the systems and trust the outputs, biasing them toward acceptance. When this reliance bias is paired with the Airlock’s finding that LLM outputs are inherently inaccurate and non-deterministic, the result is a systemic patient safety failure. The regulatory framework must therefore transition from merely asserting the clinician’s responsibility to mandating technical controls that actively counteract reliance bias, such as real-time discrepancy alerts or confidence scores. Data Protection and Ethical Considerations The deployment of AVT requires careful navigation of data protection and ethical principles. Recording conversations during consultations raises significant privacy concerns. Healthcare organisations must ensure transparent communication with patients, clearly explaining how data is collected and processed, and providing patients with clear opt-in or opt-out options to build trust. The ICO’s involvement in the AI Airlock, offering data protection by design advice, is a clear recognition of the importance of integrating privacy considerations from the earliest stages of development. Furthermore, mitigating AI bias is an essential component of the regulatory principle of Fairness. AVT models trained on non-diverse data risk perpetuating or introducing bias, leading to inaccurate and potentially harmful outcomes for specific patient populations.Compliance teams must work closely with vendors to ensure inclusivity and fairness are prioritised throughout the training and validation phases. UK Leadership in Safe AVT Regulation: A Strategic Assessment The viability of the UK becoming a global leader in the safe regulation of Ambient Voice Technologies hinges on whether the speed and depth of learning achieved by the AI Airlock can translate into a coherent, trusted, and exportable regulatory framework that effectively manages AVT-specific risks. The Leverage Point: Operationalising Airlock Findings for AVT The UK's greatest asset is its agile methodology. The AI Airlock serves as an accelerated mechanism for generating empirical evidence specifically tailored to the problems posed by generative AI in clinical settings. By focusing on real-world use cases, including devices like TORTUS, the MHRA is rapidly gathering data on core AVT regulatory challenges: managing LLM non-determinism, overseeing intended use extension, and devising robust adaptive post-market surveillance protocols. This agility allows the UK to develop detailed, risk-specific technical guidance faster than jurisdictions committed to broad, slow-moving statutory legislation. The outputs of the Airlock are already intended to inform the issuance of support templates, tools, and refined guidance for ambient scribing products by the NHS and MHRA. This rapid translation of technical findings into actionable policy signals to the global industry that the UK is not only researching the risks but is actively and quickly operationalising safety standards based on empirical evidence. This capability positions the UK as a leader in learning and adaptationwithin the AI governance sphere. The Inhibitor: Decentralisation and Regulatory Friction The core inhibitor to securing global regulatory leadership is the challenge inherent in the UK’s decentralized governance model. While the approach grants flexibility to individual regulators, it risks creating regulatory fragmentation and a perceived lack of a coherent "UK" vision. For a multinational AVT manufacturer, compliance requires navigating multiple, context-specific policy layers: the MHRA’s medical device regulations and guidance, the rigorous technical and governance requirements of the NHS Digital Technology Assessment Criteria (DTAC), specific patient safety guidance from NHS England and its devolved counterparts (e.g., NHS Wales guidance on HIC) and data governance requirements specified by the ICO. This dispersal of authority, while designed to be context-sensitive, introduces compliance friction and high transaction costs for interpretation. Global regulatory leadership is defined not just by agility, but by trusted clarity and exportability. If the technical learnings from the Airlock are dispersed across disparate, non-statutory documents issued by the MHRA, NHS, and ICO, the internal fragmentation undermines the external appeal of the framework. To become a global vanguard, the UK must integrate its deep, agile learning with a unified, transparent regulatory outcome. The current fragmented approach, if not synthesised, may discourage global MedTech companies seeking a clear, singular pathway to compliance, thereby limiting the UK's ability to truly lead the sector. The following table summarizes the key regulatory risks for AVT and the UK’s approach to mitigation: Ambient Voice Technology (AVT) Regulatory Requirements and Associated Risks. AVT Classification/Function Regulatory Pathway & Compliance Associated Safety/Governance Risks Mitigation Strategy (UK Policy/Airlock Focus) Summarisation/Documentation (Class I) UK MDR, DTAC, Self-Declaration; Mandatory CSO. Reliance Bias, Data Accuracy/LLM Errors (Non-Determinism), Privacy/Consent Violations (Recording). Human-in-Command (HIC) principle, Mandatory Clinician Validation, Explicit Patient Opt-in/Opt-out, ICO Data Protection by Design advice. Diagnosis/Management Planning (Class IIa+) UK MDR, Approved Body Review, Clinical Investigation, DTAC. Algorithmic Bias, Autonomy/Accountability Confusion, Post-Market Performance Drift (Adaptivity), Lack of Contestability. Enhanced Transparency/Explainability, Continuous Post-Market Surveillance (PMS) requirements, Airlock Phase 2 focus on Evolving AI and Diagnostics. Conclusion and Recommendations for Securing Regulatory Leadership The Medicines and Healthcare products Regulatory Agency’s AI Airlock is an indispensable regulatory instrument that validates the effectiveness of the UK’s agile, principles-based governance model in generating rapid, technical, and evidence-based solutions for complex AIaMD challenges. The Airlock has successfully moved the regulatory discourse from theoretical problems to empirical findings, most notably confirming the technical difficulty of validating generative Large Language Models due to non-determinism, a direct threat to the safety assurance of Ambient Voice Technologies. The UK possesses the technical knowledge and the regulatory mechanism (the Airlock) necessary to be a leader in the safe governance of AVT. However, achieving genuine global leadership requires overcoming the internal hurdle of regulatory fragmentation and ensuring that the safety framework is not only robust in principle but also operationally resilient against inherent socio-technical risks. Based on the analysis of the regulatory environment and the findings of the AI Airlock, the following strategic recommendations are necessary to translate agility into sustained, trustworthy leadership: Recommendation 1: Establishing LLM Performance Metrics for AVT The MHRA must immediately translate the Airlock’s findings on LLM non-determinism and inaccuracy into specific, quantitative guidance for AVT manufacturers. This guidance should move beyond qualitative statements on performance by defining acceptable variability thresholds, mandatory statistical performance metrics (e.g., bounds of acceptable error rates in text generation) and required validation methodologies tailored for the statistical nature of generative models. This targeted technical standard will provide the necessary clarity for manufacturers to comply with the principle of robustness. Recommendation 2: Integrating Technical Controls to Counter Reliance Bias The current regulatory safety framework for AVT relies heavily on the Human-in-Command (HIC) principle, but this is systemically vulnerable to clinician reliance bias. To mitigate this systemic patient safety risk, policy must mandate the incorporation of technical safeguards within AVT user interfaces. These safeguards should include providing real-time model confidence scores for generated text, implementing automated discrepancy alerts when LLM outputs deviate significantly from source conversation, and mandating enhanced explainability features that highlight the origin and certainty of key clinical data points. Such mandated technical controls proactively support the HIC principle and strengthen accountability beyond mere legal obligation. Recommendation 3: Harmonising National AVT Standards To cement its position as a global leader, the UK must address the current risk of regulatory friction caused by its decentralised structure. The outcomes and recommendations derived from the AI Airlock must be leveraged by the National Commission into the Regulation of AI in Healthcare to synthesise a unified, cross-sectoral, and enforceable national standard for AVT adoption. This framework must seamlessly integrate MHRA medical device classification, ICO data protection requirements, and NHS DTAC clinical safety criteria into a single, comprehensive guidance document. Harmonizing these standards will preserve the agility of the learning process while offering the regulatory clarity and coherence required to attract international investment and establish a globally trusted blueprint for the governance of Ambient Voice Technologies. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Key Points from The Future of HealthTech 2025 report by Silicon Valley Bank Exec Summary The single most significant key point from the Silicon Valley Bank (SVB) Future of HealthTech 2025 report is the dramatic shift of venture capital investment towards AI-enabled Provider Operations. Here's a breakdown of the central finding: Provider Operations Overtakes Alternative Care: Investment in Provider Operations (administrative and back-office functions like scheduling, documentation and billing, which is essential to the delivery of healthcare) now accounts for a massive 44% of total HealthTech funding, surpassing the previous investment leader, alternative care. The AI Driver: This surge is driven by the adoption of AI-enabled solutions aimed at solving business problems and improving efficiency. The report states that 52% of 2025 provider-operations deals involve AI. Record-Setting Investment: This sub-sector is on track to have its biggest investment year ever, projected to break its 2021 record. The Future of HealthTech 2025 Report The Future of HealthTech 2025 Report by Silicon Valley Bank (SVB) highlights a significant shift in venture capital (VC) investment, with a strong focus on AI-enabled provider operations. Key takeaways from the report include: Provider Operations Dominates Funding: Investment is shifting dramatically, with provider operations (activities like scheduling, documentation and billing) capturing 44% of HealthTech funding. This sub-sector is on track for its biggest investment year ever, projected to surpass its 2021 record. The AI Boom: AI-driven solutions are the main catalyst for this shift, transforming administrative and clinical workflows. 52% of 2025 provider-operations deals involve AI, and seed-stage AI valuations have seen a boost of around 42% since 2021. Decline in Alternative Care: Conversely, the share of investment going to alternative care has fallen sharply, from 42% in 2021 to just 9% today. M&A is the Primary Exit Strategy: As initial public offerings (IPOs) remain challenging, consolidation through mergers and acquisitions (M&A) has become the dominant exit strategy, particularly within provider operations. Concentration Risk: The report notes a concentration of capital, with mega-deals (those relying on valuation premiums, often from generalist investors) making up 38% of total Healthtech investment. A significant portion of the total invested in 2025 went to a single company. The report suggests that the HealthTech sector is becoming more focused on solving business and operational inefficiencies using AI, rather than exclusively focusing on clinical care problems. Source: https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf Key Predictions The Silicon Valley Bank (SVB) Future of HealthTech 2025 Report outlines several key predictions and ongoing trends that will shape the sector through the end of the year and beyond: 1. Dominance of AI-Enabled Provider Operations Investment Shift: The core prediction is that AI-enabled provider operations will continue to drive the sector, capturing the majority of venture capital. This sub-sector, which focuses on administrative efficiency (scheduling, documentation, billing), is on pace for its biggest investment year ever, projected to reach $8.25 Billion and account for 44% of total HealthTech investment. The Focus is Business: HealthTech is predicted to be, in the near term, an administrative sector, not a clinical one, as companies prioritise using AI to solve fundamental business and workflow inefficiencies for stronger ROI. 2. M&A as the Primary Exit Strategy Consolidation: With IPOs remaining scarce, mergers and acquisitions (M&A) will continue to be the most realistic and dominant path for exits. Consolidation, often via strategic investors and private equity "roll-ups" in the provider operations space, is expected to continue at a high pace. PE Activity: The report anticipates a record number of HealthTech private equity (PE) exits by year-end. 3. Rising Valuations and Concentration Risk AI Valuation Inflation: Median valuations for early-stage AI companies are predicted to continue climbing, potentially creating an "AI bubble." Seed-stage AI valuations have already risen approximately 42% since 2021. Concentration: Investment is predicted to remain highly concentrated in fewer, larger rounds (mega-deals), which often rely on a valuation premium provided by generalist investors. This signals a concentration risk where a large percentage of total funding is committed to a small number of top-performing companies. Silicon Valley Bank (SVB) and HealthTech SVB's relationship with the HealthTech sector is historically deep, driven by: Commercial Banking and Lending: SVB traditionally provided crucial commercial banking services, loans, and other capital to early-stage, high-growth technology and life science companies, which often struggle to get financing from traditional banks. Market Insights: The bank's reports (like the one you inquired about) are an essential source of data for investors and founders, providing deep sector-specific analysis that informs investment strategies. The Post-Collapse Context: Following the bank's collapse in early 2023, its assets and operations were acquired by First Citizens Bank. The new entity retains the commitment to serving the innovation economy, including HealthTech, leveraging the deep sector expertise of the former SVB teams. HealthTech in the US The US market is the largest and most dominant in global HealthTech investment, characterised by: Massive Investment Scale: The US has historically received the lion's share of global HealthTech VC funding, offering a massive potential customer base and significant revenue opportunities. AI and Provider Operations Focus: As highlighted in SVB's 2025 report, the US market is currently prioritising investments in AI-enabled provider operations. The focus is on solving administrative inefficiencies for clear, near-term ROI. Receptivity to Innovation: The market is generally receptive to new technologies, but the healthcare system is highly fragmented across numerous payers and providers, creating a complex regulatory and market-entry landscape. High-Stakes Environment: While offering higher reimbursement rates than many other markets, the US has intense competition and the stakes for success (and failure) are very high. HealthTech in Europe The European market is known for its rapid growth and fragmentation, which presents both unique opportunities and challenges: Fastest-Growing Region (Historically): Europe, and particularly the UK, has been one of the fastest-growing regions for HealthTech investment, although it started from a lower base than the US. UK Leadership: The United Kingdom (especially the "Golden Triangle" of London, Oxford, and Cambridge) is typically the leading hub for HealthTech investment in Europe, known for its strong research base and proximity to the NHS. Market Fragmentation: A major challenge is the fragmentation of healthcare systems across different countries (France, Germany, Nordic regions, etc.). Each country maintains control over its own national system, leading to variations in procurement, reimbursement, and regulatory approval, which complicates scaling across the continent. Focus Areas: European companies are also innovating across various areas, including digital therapeutics, chronic care management, and physician support tools, often driven by different policy and public health priorities compared to the US. Regulatory Challenges: Navigating varied national reimbursement policies, language barriers, and the complexities of regulations like the EU's Medical Device Regulation (MDR) remain significant hurdles for European startups trying to scale Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk